---
document_datetime: 2023-09-21 17:48:46
document_pages: 47
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf
document_name: mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf
version: success
processing_time: 12.44578
conversion_datetime: 2025-12-28 12:51:33.252934
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 July 2011 EMA/CHMP/668488/2011 Committee for Medicinal Products for Human Use (CHMP)

## CHMP assessment report

## Mercaptopurine Nova Laboratories

national non-proprietary name: mercaptopurine Inter

Procedure No. EMEA/H/C/002022

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| f the medicinal product: Name o                | purine Nova Laboratories Mercapto                                                                                                          |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | ories Ltd. House Wigston YL United Kingdom Nova Laborat Martin Gloucester Crescent Leicester LE18 4                                        |
| Active substance:                              | mercaptopurine monohydrate                                                                                                                 |
| Name/Common Name: International Nonproprietary | mercaptopurine                                                                                                                             |
| Pharmaco-therapeutic group (ATC Code):         | Purine analogues 1BB02) (L0                                                                                                                |
| tic indication(s): Therapeu                    | Mercaptopurine Nova Laboratories is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children |
| Pharmaceutical form(s):                        | Oral suspension                                                                                                                            |
| Strength(s):                                   | 20 mg/ml                                                                                                                                   |
| Route(s) of administration:                    | Oral use                                                                                                                                   |
| Packaging:                                     | bottle (glass)                                                                                                                             |
| Package size(s):                               | 1 bottle + 1 bottle adaptor + 2 oral syringes                                                                                              |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..........................                                               | ....................5                                                                                   |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier..............................................................                        | ...................... 5                                                                                |
| 1.2. Manufacturers .............................................................................                    | ...................... 7                                                                                |
| 1.3. Steps taken for the assessment of the product                                                                  | ...................... 9 .................................                                              |
| 2. Scientific discussion ............................................................                               | ..................10                                                                                    |
| 2.1. Introduction                                                                                                   | 10 .................................................................................................... |
| Type of application and aspects on development .....................................                                | .................... 12                                                                                 |
| 2.2. Quality aspects ............................................................................                   | .................... 12                                                                                 |
| 2.2.1. Introduction .............................................................................                   | .................... 12                                                                                 |
| 2.2.2. Active Substance.......................................................................                      | .................... 12                                                                                 |
| 2.2.3. Finished Medicinal Product ..........................................................                        | .................... 14                                                                                 |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.........                                       | .................... 17                                                                                 |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                           | 18 .....................                                                                                |
| 2.2.6. Recommendations for future quality development ..........................                                    | .................... 18                                                                                 |
| 2.3. Non-clinical aspects.......................................................................................... | 18                                                                                                      |
| 2.3.1. Introduction .............................................................................                   | .................... 18                                                                                 |
| 2.3.2. Pharmacology...........................................................................                      | .................... 18                                                                                 |
| 2.3.3. Pharmacokinetics ......................................................................                      | .................... 19                                                                                 |
| 2.3.4. Toxicology................................................................................                   | .................... 20                                                                                 |
| 2.3.5. Ecotoxicity/environmental risk assessment....................................                                | .................... 24                                                                                 |
| 2.3.6. Discussion on non-clinical aspects................................................                           | .................... 24                                                                                 |
| 2.3.7. Conclusion on the non-clinical aspects ..........................................                            | .................... 27                                                                                 |
| 2.3.8. Recommendation for future pre-clinical development......................                                     | .................... 27                                                                                 |
| 2.4. Clinical aspects                                                                                               | 27 ................................................................................................     |
| 2.4.1. Introduction .............................................................................                   | .................... 27                                                                                 |
| 2.4.2. Pharmacokinetics ......................................................................                      | .................... 28                                                                                 |
| 2.4.3. Pharmacodynamics....................................................................                         | .................... 33                                                                                 |
| 2.4.4. Discussion on clinical pharmacology .............................................                            | .................... 33                                                                                 |
| 2.4.5. Conclusions on clinical pharmacology                                                                         | 35 ...............................................................                                      |
| 2.5. Clinical efficacy ............................................................................                 | .................... 36                                                                                 |
| 2.5.1. Discussion on clinical efficacy ......................................................                       | .................... 36                                                                                 |
| 2.5.2. Conclusions on the clinical efficacy...............................................                          | .................... 37                                                                                 |
| 2.5.3. Recommendations for future clinical efficacy development...............                                      | .................... 38                                                                                 |
| 2.6. Clinical safety                                                                                                | .................................................................................................. 38   |
| 2.6.1. Discussion on clinical safety ............................................................................   | 39                                                                                                      |
| 2.6.2. Conclusions on the clinical safety.....................................................................      | 41                                                                                                      |
| 2.6.3. Recommendations for future clinical safety development.....................................                  | 41                                                                                                      |
| 2.7 Pharmacovigilance                                                                                               | ............................................................................................ 41         |
| 2.8 User consultation                                                                                               | .............................................................................................. 42       |
| 4. Recommendations...............................................................................43                 |                                                                                                         |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

S ACCI

d Cancer Information Automated Childhoo

c Leukaemia asti Acute Lymphobl

ount Absolute neutrophil c

Master File Active Substance

anthine-guanine phosphoribosyl transferase Hypox

matography High Pressure Liquid Chro

for Research on Cancer International Agency

for Harmonisation International Conference

se Effect Level Lowest Observed Adv er

ion Application Marketing Authorisat

ry Mass Spectomet

P mTIM

onophosphate Methylthioinosine m

L NOAE

Plan ic Investigation Paediatr

U PS R

fety Update Report Periodic Sa

TGN

Thioguanine nucleotides

TIMP

Thioinosine monophosphate

TPMT

Thiopurine S-methyltransferase

UKALL

United Kingdom Childhood Acute Lymphoblastic Leukaemia Trial

USP

United-States Pharmacopoeia

UV

Ultraviolet

Xanthine oxidase

6- P M

6-Mercaptopurine

ALL

ANC

ASMF

EFS

Event Free Survival

EP

European Pharmacopoeia

GC

Gas Chromatography

HDPE

High Density Polyethylene

HGPRT

HPLC

IARC

ICH

IR

Infrared

LO E A L

MAA

MS

No Observed Adverse Effect Level

NMR

Nuclear Magnetic Resonance

PIP

XO

<div style=\"page-break-after: always\"></div>

## mation on the procedure 1. Background infor

## 1.1. Submission of the dossier

ion  for  Marketing to the European Medicines Agency (EMA) for Mercaptopurine Nova Laboratories, through egulation (EC) No A/CHMP  on The  applicant  Nova  Laboratories  Ltd.  submitted  on  2  June  2010  an  applicat Authorisation the centralised procedure falling within the Article 3(1) and point 4 of Annex of R 726/2004.  The  eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EM 22 October 2009.

product  EU/3/09/628  on han medicinal product in lated  prevalence  of this condition was 1. Mercaptopurine  Nova  Laboratories  was  designated  as  an  orphan  medicinal 30 April  2009.  Mercaptopurine Nova Laboratories was designated as an orp the  following  indication:    Treatment  of  acute  lymphoblastic  leukaemia.  The  calcu 2 per 10,000 EU population.

n, the Committee for Orphan ) reviewed the designation of Mercaptopurine Nova Laboratories as an ew can be found on ind Medicine/Human medicines/Rare disease designations Following the CHMP positive opinion on this marketing authorisatio Medicinal Products (COMP orphan medicinal product in the approved indication. The outcome of the COMP revi the Agency's website : ema.europa.eu/F .

The legal basis for this application refers to Article 10(3) of Directive 2001/83/EC.

The chosen reference product is:

been authorised in accordance with Community provisions Reference medicinal product which is or has in force for not less than 6/10 years in the EEA:

- Product name, strength, pharmaceutical form: Puri-Nethol 50 mg Tablets -
- Limited Trading as GlaxoSmithkline UK -Marketing authorisation holder: The Wellcome Foundation
- -Date of authorisation: 12 December 1986
- ed Kingdom -Marketing authorisation granted by: Unit
- 003/5227R -Marketing authorisation number: PL 00

tate  where  the  application  is Reference  medicinal  product  authorised  in  the  Community/Member  S made:

- -Product name, strength, pharmaceutical form: Puri-Nethol 50 mg Tablets
- laxoSmithkline UK -Marketing authorisation holder: The Wellcome Foundation Limited Trading as G
- -Date of authorisation: 12 December 1986
- -Marketing authorisation granted by: United Kingdom
- -Marketing authorisation number: PL 00003/5227R

Differences compared to the reference medicinal product: change in pharmaceutical form

The  application  submitted  is  composed  of  administrative  information,  complete  quality  data  and  a bioequivalence  study  with  the  reference  medicinal  product  Puri-Nethol  instead  of  non-clinical  and clinical data unless justified otherwise.

<div style=\"page-break-after: always\"></div>

The applicant applied for the following indication: Mercaptopurine Nova Laboratories is indicated for the treatment of acute lymphoblastic leukaemia (ALL). It may be utilised in induction and consolidation phases of therapy of ALL. It is particularly indicated, however, for the continuous phase of therapy.

<div style=\"page-break-after: always\"></div>

## tion on Paediatric requirements Informa

Not applicable.

## tion relating to orphan market exclusivity Informa

## Similarity

cle 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application contained a critical report addressing the possible similarity with authorised cinal products. Pursuant to Arti orphan medi

## ity Market Exclusiv

Not applicable.

## vice Scientific Ad

. The Scientific Advice pertained to insert quality, non-clinical and clinical aspects of the dossier. The applicant received Scientific Advice from the CHMP on 24 July 2008

## s Licensing statu

The product was not licensed in any country at the time of submission of the application.

## Manufacturers 1.2.

## ance Manufacturer of the active subst

ulu Finland Fermion Oy Lääketehtaantie 2 Sanginsuu FIN-90650 O

## of the finished product Manufacturer

es Ltd. scent Leicester LE18 4YL United Kingdom Nova Laboratori Martin House Gloucester Cre Wigston

## Manufacturer responsible for batch release

Nova Laboratories Ltd. Martin House Gloucester Crescent Wigston Leicester LE18 4YL United Kingdom

<div style=\"page-break-after: always\"></div>

## 1.3. Steps taken for the assessment of the product

P and the evaluation teams were: The Rapporteur and Co-Rapporteur appointed by the CHM

Rapporteur: Tomas Salmonson

Co-Rapporteur: Pierre Demolis ne Papadouli The EMA Product Team Leader: Ire

-  The application was received by the EMA on 2 June 2010.
- d on 21 July 2010.  The procedure starte
- on 8 October 2010 HMP members on 8 x 2).  The Rapporteur's first Assessment Report was circulated to all CHMP members (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all C October 2010 (Anne
- meeting on 18 November 2010, the CHMP agreed on the consolidated List of Questions the applicant on 19  During the to be sent to the applicant. The final consolidated List of Questions was sent to November 2010 (Annex 3).
- ns on 11  The applicant submitted the responses to the CHMP consolidated List of Questio February2011.
-  The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 25 March 2011 (Annex 4).
- tanding Issues to be  During the CHMP meeting on 14 April 2011, the CHMP agreed on a List of Outs addressed in writing by the applicant (Annex 5).
- ues on 23 May 2011.  The applicant submitted the responses to the CHMP List of Outstanding Iss
- st of outstanding issues to all CHMP members on 9 June 2011 (Annex 6).  The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the Li
- of outstanding issues to  During the CHMP meeting on 23 June 2011, the CHMP agreed on a 2 nd  list be addressed in writing by the applicant (Annex 7).
- ist of Outstanding Issues on 1 July 2011  The applicant submitted the responses to the CHMP L
-  The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the 2 nd List of Outstanding Issues to all CHMP members on 11 July 2011 (Annex 8).
-  During the meeting on 21 July 2011, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Mercaptopurine Nova Laboratories on 21 July 2011.
-  The CHMP adopted a report on similarity of Atriance, Evoltra, Glivec and Sprycel with Mercaptopurine Nova Laboratories on 17 March 2011 (Appendix 1).

<div style=\"page-break-after: always\"></div>

## ic discussion 2. Scientif

## ion 2.1. Introduct

## Problem statement

ells  (blast  cells),  a erally  refined  using s  of  bone  marrow'B' cell, and thence d  'B'  cell  leukaemia.  The  clinical  and  biological  characterisation  of  a  patient's Acute  Lymphoblastic  Leukaemia  (ALL)  is  a  malignant  proliferation  of  lymphoid  c biologically  heterogeneous  disorder among  patients. A  clinical  diagnosis  is  gen morphologic,  immunologic,  cytogenetic,  biochemical  and  molecular  genetics  test derived blasts. These tests classify patients into two broad subsets, namely 'T' and into  subtypes  of  'T'  an disease are used together to direct treatment and as a guide to prognosis.

e third of childhood mes, the cause of ALL is the most common malignancy diagnosed in children, representing nearly on cancers. Although a few cases of ALL are associated with inherited genetic syndro ALL remains largely unknown.

volvement in ALL. node ,  hepatic  or enlargement  can with associated respiratory difficulty. Central nervous system and, in boys, testicular involvement is less common. Signs or symptoms of CNS involvement include headache, ns  of  cranial  nerve ntly  involved)  may ological symptoms, painless  testicular The lymph nodes, liver and spleen are the most common sites of extra-medullary in These organs and tissues are enlarged as a result of infiltration by blasts. Lymph splenic  enlargement  may  be  asymptomatic.  However,  intra-thoracic  lymph  node present as a mediastinal mass nausea  and  vomiting,  lethargy,  irritability,  neck  stiffness  and  papilloedema.  Sig involvement  (the  third,  fourth,  sixth  and  seventh  cranial  nerves  are  most  freque occur. ALL can also present as an intracranial or spinal mass causing numerous neur most  of  which  are  due  to  nerve  compression.  Testicular  involvement  appears  as enlargement and is most often unilateral.

val of patients with ethotrexate  were agents  have  been dexamethasone), e d for children with The achievement of a complete remission is a prerequisite for the long-term survi acute  leukemia.  First  remissions  in  ALL  using  amethopterin,  an  analogue  of  m demonstrated  in  1948  (Sidney  Farber).  Since  then,  combinations  of  various successful in inducing remissions, such as vincristine and prednisone(or Daunorubicin and L-asparaginase (or PEG-L-asparaginase). The use of additional drugs, such as th anthracyclines (daunorubicin or doxorubicin) or cyclophosphamide is often reserve high-risk ALL.

re killed during the y  100  million  cells. n with ALL relapsed ssion induction phase.  In  the  late  1960s,  investigators  at  St.  Jude  Children's  Research  Hospital  developed  a  \"total ach  for  the  treatment  of  children  with  ALL.  The  model  included  remission  induction, continuation chemotherapy with or without intensification, and preventive CNS therapy. The choice of 6-mercaptopurine, nations.  The  best ercaptopurine  and nation show a 42% disease-free  survival  rate  for  children  with  initial  WBC  counts  of  fewer  than  25,000  cells  per It  has  been estimated that approximately two to three logs of leukemic blasts a induction  phase  of  therapy,  leaving  a  residual  leukemic  burden  of  approximatel Therefore, additional treatment is necessary to prevent relapse. In the past, childre within a median of 4 to 6 months when treatment was not continued beyond the remi therapy\"  appro continuation therapy was empiric. The early St. Jude studies evaluated methotrexate,  cyclophosphamide,  and  cytarabine  in  various  doses  and  combi outcome  was  achieved  in  patients  who  received  2  to  3  years  of  daily  oral  6-m weekly methotrexate. Long-term follow-up of patients treated with this latter combi L, whereas it was only 16% for all other patients. Recent clinical trials have confirmed the importance of intensive  re-induction  therapy  or  dose-intensified  antimetabolite  therapy,  even  for  patients  with favorable risk features.

## About the product

The development of the purine analogues in cancer chemotherapy (deVita et al 2005) began in the early  1950s  with  the  synthesis  of  thiopurines.  The  purine  analogues  6-mercaptopurine  (6-MP)  and 6-thioguanine (6-TG) continue to be used principally in the management of acute leukemia. 6-MP has an  important  role  in  maintenance  therapy  for  acute  lymphoblastic  leukemia  (ALL),  whereas  6-TG  is

<div style=\"page-break-after: always\"></div>

ues  have  a  single MP is a structural inactive  pro-drug st  but  requires  cellular  uptake  and  intracellular  anabolism  to thioguanine  nucleotides  for  cytotoxicity.  Finally,  azathioprine  is  a  derivative  of  6-MP  and  acts  as  a prodrug to provide sustained release of 6-MP. active  in  remission  induction  and  in  maintenance  therapy  for  AML.  These  analog substitution of a thiol group in place of the 6-hydroxyl group of the purine base. 6analogue  of  hypoxanthine,  whereas  6-TG  is  an  analogue  of  guanine.  6-MP  is  an which  acts  as  a  purine  antagoni

Figure 1 The metabolic fate of 6-Mercaptopurine

<!-- image -->

6-MP in its monophosphate nucleotide form inhibits de novo purine synt interconversion reactions, whereas the nucleotide triphosphate metabolites are in into nucleic acids. The relative contribution of each of these actions to the mechanism of cytotoxi unclear.  6-MP  is  converted  to  monophosphate  forms  by  hypoxanthine-guani transferase  (HGPRT).  The  ribonucleotide  monophosphate  inhibits  the  first  step synthesis  catalyzed  by  gl hesis and purine corporated directly city is ne  phosphoribosyl of de  novo purine utamine  phosphoribosylpyrophosphate  aminotransferase  and  block  the ucleotide synthesis ivation of 6-MP and ibonucleotide and cellular  RNA  and DNA, respectively. In some experimental model systems, incorporation of thiopurine nucleotides into conversion of inosinic acid to adenylic acid or to guanylic acid. Inhibition of purine n leads to the buildup of 5'-phosphoribosyl-1-pyrophosphate, which facilitates the act 6-TG to their active nucleotide forms by HGPRT. Both thiopurine r deoxyribonucleotide  metabolites  are  formed,  which  can  then  be  incorporated  into DNA correlates with cytotoxicity.

blished  over  many tional trials. Consequently, all treatment protocols used by EU member nations for treating childhood ALL include oral 6-MP. Actual daily doses of 6-MP for the 25 mg. There is no justed  to  suit  the The  efficacy  of  6-mercaptopurine  (6-MP)  for  the  treatment  of  ALL  has  been  esta years through a number of national and interna treatment of childhood ALL appear to vary from as little as 7.5 mg to a high of 1 maximum  dose  of  6-mercaptopurine  recommended,  as  the  dosage  should  be  ad individual patient, based on absolute neutrophil count (ANC) and platelet count.

for the patients and ance therapy, most king whole tablets be crushed, which Currently, 6-MP is only available as oral tablet which poses a number of difficulties the  care  giver,  especially  when  used  in  children.  However,  for  standard  mainten children need doses other than that obtained from the 50 mg tablet. In addition, ta can be difficult especially in young children and that means that the tablet has to also involves safety risks for the person handling the tablet.

The rationale for the development of Novapurine oral suspension was that a liquid formulation would provide  advantages  over  the  single-strength,  solid  tablet  for  the  treatment  of  a  serious  disease  in children.  The  proposed  oral  suspension  offers  more  flexibility  and  accuracy  in  terms  of  dosing  and improved  ease  of  administration  (and  hence  compliance)  for  children.  This  is  particularly  important given that the ideal dosing is to titrate according to haematological values.

Mercaptopurine Nova Laboratories oral suspension (20 mg/ ml) contains 6-MP as monohydrate. The applicant applied for the following indication: treatment of acute lymphoblastic leukaemia (ALL). It may be utilised in induction and consolidation phases of therapy of ALL. It is particularly indicated, however, for  the  continuous  phase  of  therapy .  The  finally  approved  indication  is: Mercaptopurine  Nova Laboratories  is  indicated  for  the  treatment  of  acute  lymphoblastic  leukaemia  (ALL)  in  adults, adolescents and children . The dose is governed by cautiously monitored haematotoxicity and the dose should be carefully adjusted to suit the individual patient in accordance with the employed treatment

<div style=\"page-break-after: always\"></div>

reatment,  starting  or  target  doses  generally  vary  between 25-75 mg/m 2  body surface area (BSA) per day. protocol.  Depending  on  phase  of  t

## Type of application and aspects on development

ment. The request expected  to  facilitate  the i-Nethol 50 mg tablet) has been  used  to  treat  children  for  many  years  with  good  treatment  results,  and  therefore  the  unmet medical need was questioned. The Applicant submitted on  22 nd  February 2010 a request for accelerated assess was  rejected  since,  even  though  an  age  appropriate  formulation  is administration of 6-MP to children, the currently available formulation (Pur esignated as an Orphan Drug for ALL on 30 April 2009 (EU/3/09/628). Mercaptopurine was d

## 2.2. Quality aspects

## 2.2.1. Introduction

ure  for  Mercaptopurine  Nova t has been granted This  Marketing  authorization  application  concerns  a  centralized  proced Laboratories 20mg/ml oral suspension from Nova Laboratories Ltd. The drug produc orphan medicinal product designation on 30 April 2009.

tion,  of  Directive m  'the  Welcome er 1986. The  application  is  submitted  in  accordance  with  Article  10(3),  hybrid  applica 2001/83/EC.  The  reference  medicinal  product  is  Puri-Nethol®  50  mg  tablets,  fro Foundation Limited', authorized in the UK since 12 Septemb ance. The finished product is an oral suspension containing Mercaptopurine as active subst

re, supplied with a daptor (HDPE) and two graduated oral syringes for administration purposes. It is packed in 100 ml glass bottle, with tamper evident, child resistant (CR) closu bottle a

The excipients are the following: xanthan gum  (viscosity modifier), aspartame (sweetener), uice (flavouring agent), methyl parahydroxybenzoate and propyl parahydroxybenzoate (antimicrobial preservative), water (diluent/vehicle). concentrated raspberry j child resistant (CR) syringes  for  administration The container closure system consists of a 100 ml glass bottle, with tamper evident, closure,  supplied  with  a  bottle  adaptor  (HDPE)  and  two  graduated  oral purposes.

## 2.2.2. Active Substance

The  active  substance  is  Mercaptopurine  monohydrate.  Mercaptopurine  is  a  well-established  active substance  that  has  been  marketed  for  several  decades  as  Puri-Nethol®  tablets.  Mercaptopurine  is described in the European Pharmacopoeia (PhEur) and US Pharmacopoeia (USP).

The physico-chemical properties of the active substance (mercaptopurine monohydrate or 6H-Purine6-thione, 1,7-dihydro-,monohydrate Purine-6-thiol monohydrate) have been adequately detailed including properties such as appearance, melting point, density, solubility, pKa, isomerism (none) and polymorphism (none observed).

The structural formula is shown below:

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Manufacture

n step and the process controls have been provided along with a synthesis chart. Information related to the reagents and raw tory. The description of the manufacturing process includes a micronisatio materials (solvents, catalysts) and conditions of synthesis is considered satisfac r File (ASMF). Full details of the manufacturing process are presented in an Active Substance Maste

h  of  in-house  reference s  Spectrometry),  IR The  structure  of  the  active  substance  has  been  fully  elucidated  on  one  batc material  by 13 C  NMR  and 1 H  NMR  (Nuclear  magnetic  Resonance),  MS  (Mas (infrared), and UV (ultraviolet) spectroscopy.

potential impurities of mercaptopurine including their structure and limits was ication including organic impurities, degradation products and residual solvents. A discussion on presented in the appl

## Specification

ntification (UV rl-Fischer), organic s (GC), residual solvents (GC), related substances (HPLC), particle size distribution (laser diffraction). Specification of the active substance mercaptopurine includes the following tests: ide Ph.Eur. and IR), sulphated ash (Ph.Eur.), assay (Ph.Eur.), water content (Ph.Eur. Ka volatile impuritie e Ph.Eur. monograph. ternal specifications for related substances, ow  the  ICH  Q3C Specifications applied by the drug product manufacturer are in accordance with th Additionally, the active substance manufacturer applies in residual  solvents,  and  particle  size  distribution.  Limits  for  residual  solvents  are  bel recommended levels.

e Ph.Eur. methods al tests, where in-house methods are used and described. The validation of the in-house methods has been presented and followed the ICH guidelines. Regarding the analytical methods, the active substance manufacturer has used th except for the addition the ASMF holder and anufacturer and the results were found in line with the specification. Results were presented for 3 commercial scale batches of mercaptopurine from from the finished product m

vents are set by ns for particle size le. The results were compliant with the Ph.Eur. Additional specifications for residual sol the drug substance manufacturer and are in accordance with ICH Q3C. Specificatio were considered acceptab

The primary packaging is made of transparent polyethylene bags, placed into black bags and then in plastic drums. The material complies with the Ph.Eur. The in-house specification includes identification by IR and thickness. fibre or terials and monograph 3.1.3) lts.  A certificate of suitability (CEP) has been granted by EDQM for the active substance in the packaging material 'transparent polyethylene bag', therefore the information provided was deemed sufficient. The ASMF holder declared that the polyethylene bag is suitable for pharmaceutical ma provided certificate of analysis from the supplier (stating conformity to the Ph. Eur. and metal residues analysis resu

## Stability

Stability data have been presented on 10 commercial scale batches  kept in the commercial packaging under ICH long term conditions (up to 60 months at 25°C/60%RH) and accelerated conditions (6 months at 40°C/75%RH). In addition, a forced degradation study has been performed and showed that the HPLC method was stability indicating.

<div style=\"page-break-after: always\"></div>

d for assay, water ted (40°C/75%RH) Under long-term and accelerated conditions, no significant changes have been note content, and related substances. Results on long term (25°C/60%RH) and accelera conditions were conformed to the specification throughout the duration of the study.

A satisfactory re-test period under the recommended storage conditions (room temperature, protected from light) has been justified.

## Comparability exercise for Active Substance

Not applicable

## 2.2.3. Finished Medicinal Product

on of ent, child resistant Mercaptopurine Nova Laboratories 20mg/ml oral suspension is an aqueous suspensi mercaptopurine. It is packed in 100ml amber glass bottles, closed with tamper evid cap.

um (viscosity modifier), arahydroxybenzoate imicrobial preservative), water (diluent/vehicle). The composition of the concentrated raspberry juice has been detailed. The medicinal product contains the following compendial excipients: xanthan g aspartame (sweetener), concentrated raspberry juice (flavouring agent), methyl p and propyl parahydroxybenzoate (ant er glass bottles at a nominal fill of 100 ml, and closed with a se of a dosing e bottle and other The suspension is filled into amb polyethylene screw cap. In use, a polyethylene adaptor is inserted to facilitate the u syringe. Graduated 1 ml and 5 ml dosing syringes are provided with each bottle. Th components are packed in a cardboard carton.

## Pharmaceutical Development

several decades in ed as 'practically insoluble in water' in the Ph labile in both strong d solubility reduces g  procedure,  and Mercaptopurine is a well studied active substance that has been on the market for the EU in the form of a tablet formulation. It is describ Eur therefore is an ideal candidate for a suspension formulation. Mercaptopurine is acid and base; but in neutral pH it is stable in suspension. Furthermore, the limite the  unpleasant  taste  of  the  active  substance  and  simplifies  the  taste  maskin consequently also patient compliance.

ng  suspension he  content  uniformity  of  the  product,  and  improved  also  compliance  by The  fine  particle  size  distribution  of  the  drug  substance,  as  chosen,  helps  improvi physical  stability  and  t eliminating 'grittiness' from larger particles.

minimisation of the Since Mercaptopurine is cytotoxic, the formulation design has to take into account potential for unnecessary contact with users and patients during use.

in  Mercaptopurine  20  mg/  ml  suspension  are  well  established  compendial armacopoeia  1988 e to the applicant's of mercaptopurine suspensions and has since been supported  by  stability  tests.  The  strength  of  the  formulation  is  chosen  to  give  a  typical  oral  drug product dose volume of 1-5 ml. The  excipients  included excipients  (Ph.Eur  except  the  raspberry  flavour  that  complies  with  the  British  Ph monograph). Compatibility of the active substance with the excipients is known du earlier experience of extemporaneous manufacture

Excipients  used  are  namely:  xanthan  gum  (viscosity  agent),  aspartame  (sweetener),  concentrated raspberry juice (flavouring agent), methyl para-hydroxy benzoate (antimicrobial preservative), propyl para-hydroxy benzoate (antimicrobial preservative),

Concentrated raspberry juice is prepared from the juice of rubus lutaeus L. with sucrose added to adjust the weight per ml in the final concentrate. Sulphur dioxide is also added as a preservative and limited without safety concern.

The role of xantham gum and raspberry flavour and their concentration in the finished product are well justified.  Xanthan  gum  modifies  the  viscosity  and  thus  physically  stabilises  the  suspension  to  allow accurate dosing.

<div style=\"page-break-after: always\"></div>

as  not  considered ver the 2 to 3 year Aspartame  was  used  to  improve  the  taste.  Sucrose  as  a  sweetening  agent  w appropriate for chronic medication, due to the potential for causing dental caries o treatment period.

re  included  in  the The preservatives methyl parahydroxybenzoate and propyl parahydroxybenzoate a formulation, due to the multidose use of the product.

ng ent The  Applicant  intends  to  introduce  a  revised  preservative  system  by  variation  of  the  Marketi Authorization. Refer to section 2.2.6. Recommendations for future quality developm

The analytical procedures used are those described in the Ph.Eur. monograph. Validation was therefore e excipients are all h excipient. not deemed necessary. No justification of the specification was requested since th compendial. Certificates of analysis in line with the specification are included for eac urinethol  tablets,  . ients. Furthermore, Although mercaptopurine has been available for several decades in the form of P there was a need for another formulation to address the treatment of paediatric pat the suspension may also be of help for adult patients with swallowing difficulties.

lation, which is not t  is  manufactured  under  GMP  conditions  in  the  UK,  developed  from  it  with  minimal change from the composition point of view. The proposed formulation is an extension of an already successful 'Specials' formu authorised  bu ets.  The The  bioavailability  of  the  suspension  has  been  assessed  and  compared  to  Purinethol  tabl suspension was shown to be systemically available faster and more reproducibly.

pted, especially by This suspension should allow more accurate dosing and should be more easily acce paediatric patients.

a  standard ation  of  the  base, not  changed  much t.  The  process  allows  to  maintain  the  active substance homogeneity until the end of the filling step. The  manufacturing  process  has  been  adequately  described  and  can  be  considered  as process.  The  process  is  simple  and  can  be  divided  into  three  parts:  prepar incorporation  of  the  active  substance  and  filling.  The  manufacturing  process  has since  the  beginning  of  the  pharmaceutical  developmen nt cap. An adaptor are  provided  with nth treatment. The ng overage of 3 ml olume of 100 ml can be withdrawn. The drug product is filled into 100 ml amber type III glass bottles with child-resista is  inserted  for  in-use  dose  measurements  and  graduated  1  ml  and  5  ml  syringes each bottle. The container size is chosen to provide sufficient suspension for one mo description and the choice of the container have been appropriately detailed. A filli is added to ensure that a nominal v

ad. In use the cap neck of the bottle l dosing syringes are provided with each bottle. n  that  the  contact n aqueous vehicle. The drug product is packaged in a glass bottle with a cap/expanded polyethylene w is removed, an adaptor for use with HDPE oral dosing syringes is inserted into the and the original cap is replaced. Graduated 1 and 5 m No significant  interaction  between  the  product  and  the  syringe  is  anticipated  give period during dosing is brief and that the active substance is highly insoluble in a Stability  testing  has  shown  no  evidence  of  interaction  between  the  active  substance  and  the  PE compounds of the container closure system.

ents for type III for lude:  appearance,  cleanliness, c  resistance  test  A,  and  light transmission. Certificate of analysis from supplier includes physical tests and declares compliance with as described above and with directive 1935/2004. The bottles are amber soda-lime silica glass and meet the US and PhEur requirem hydrolytic  resistance  and  for  light  transmission.  Specifications  inc comparison  with  a  reference  100ml  bottle,  filling  volume,  hydrolyti EP requirements

The cap is composed of: inner layer of polypropylene (PP), outer layer of high density polyethylene nd a liner (wad) of expanded polyethylene. The liner is in direct contact with the medicinal product. The supplier has declared that the outer layer is compliant with the 2002/72/EC directive. (HDPE), a

The in-house specifications for the cap include: appearance, cleanliness, comparison with reference cap, cap fit compatibility, identification of polyethylene by IR spectroscopy.

It has been confirmed that the material in the wad, and all other materials in contact with the product, comply with 2002/72/EC.

In addition, the cap is child resistant and complies with the standard EN ISO 8317:2004.

## Adventitious agents

## Not applicable

<div style=\"page-break-after: always\"></div>

## Manufacture of the product

bens solution, then dispersion of Mercaptopurine, and filling d  in-process The manufacturing process can be summarised as follows: preparation of the para dissolution of aspartame, xanthan gum, raspberry flavour and of  the  bottles.  Process  parameters  have  been  controlled  in  a  satisfactory  manner  an controls included tests such as: mixing speed, mixing duration, bottle filling.

en manufactured at tion  of  the  process ed  on  the  product rance, pH, density, reservatives  content,  aspartame  content, uniformity of mass of delivered dose, dissolution, viscosity and particle size, data on the filling weight. ariability. The data an stand for a preliminary process validation study. It the manufacturer has good control over the process. Three consecutive batches of mercaptopurine 20 mg/5 ml oral suspension have be production  scale.  Process  verification  data  have  been  provided  including:  descrip parameters,  IPC  data  on  the  bulk  before  addition  of  Mercaptopurine,  data  record after filling (beginning, middle and end of the filling step). The tests included: appea identification  of  drug  substance,  drug  substance  content,  p All  data complied with the specifications with an adequate intra and inter batch v presented for the three industrial scale batches c can be considered that in  any  excipient  of It  is  declared  that  Mercaptopurine  Nova  Laboratories  20mg/5ml  does  not  conta human or animal origin. Therefore no TSE risk is anticipated.

## Product specification

The release and shelf life specifications of the Mercaptopurine 20 mg/ml suspension are adequate for sual), pH (Ph.Eur.), iformity of mass of delivered doses ( Ph Eur ), viscosity ( Ph. Eur.) , particle size ( Ph. P method), related ontent  (HPLC),  homogeneity  of  suspension,  aspartame  content this pharmaceutical form and the following parameters are tested: appearance (vi density (Ph.Eur.), un Eur. ), dissolution (Ph. Eur. ) , mercaptopurine content (HPLC), identification (HPLC, B substances  (HPLC),  preservative  c (HPLC), microbial contamination (Ph.Eur.).

ds  have  been  described  and  in-house  methods  validated  in  accordance  with  I CHQ2 guidelines. Analytical  metho

Results  for  3  consecutive  production  scale  batches  of  the  medicinal  product  were  presented, representative of the manufacturing process.

. Specifications are impurities  levels  are  below  the  ICH  limits  and  do  not  present  any  specific Batch analysis results conform to specifications and are consistent, batch-to-batch adequately  justified  and toxicological concern.

## Stability of the product

ng term (5°C) and r 12 months at 5°C Stability studies have been conducted on 3 production scale batches under ICH lo accelerated conditions (25°C/60%RH , 40°C/75%RH). The batches were studied fo and 25°C and 6 months at 40°C.

pearance,  density, lution,  mercaptopurine  content, identification,  related  substances,  preservative  content,  homogeneity  of  suspension,  aspartame content, microbial contamination. The  following  parameters  were  investigated  during  those  stability  studies:  ap uniformity  of  mass  of  delivered  doses,  viscosity,  particle  size,  disso

The analytical methods used were the same as those ones used for the control of the finished product. Post approval, the manufacturer commits to place on stability one batch per year,

The only parameters showing any trend on storage at 25°C/60%RH are aspartame content, viscosity and propyl parahydroxybenzoate content. The reductions were minimal and results remained within the finished product acceptance criteria. Therefore, the product remains in specification for at least a year at 25°C. Preservative efficacy data is included at 12 months for 2 batches performed both by the finished product manufacturer and at an external specialist contract laboratory. The results complied with the requirements of Ph.Eur. In addition preservative efficacy results were also included for one batch after for 18 months at 25°C/60%RH and these results also complied with Ph.Eur.

<div style=\"page-break-after: always\"></div>

tem,  to  eliminate preservation. As an interim measure, agreed at a clarification meeting, a shelf life of 1 year is proposed when the A  change  management  protocol  is  in  place  to  re-formulate  the  preservative potential toxicity due to propyl hydroxybenzoate, and to improve the robustness of fungal sys product is stored at a temperature not exceeding 25°C.

included in the vering  twelve  batches  and  3-26  months  data  under  ambient  conditions.  Assay results were reported as variable, which may be caused by factors outside of the control of the drug naffected  with  no In addition, Supportive stability data for  the  extemporaneous  formulation  is documentation,  co product  manufacturer.  The  stability  of  mercaptopurine  in  the  suspension  was  u evidence of degradation.

lass  bottle  as  the ility  study  for  the on  lux  hours  and  2492  watt nt protection for mercaptopurine  is ent in the Ph. Eur. light. The  packaging  for  mercaptopurine  oral  suspension  consists  of  a  100ml  amber  g primary  container  within  a  cardboard  box  secondary  container.  A  photo-stab suspension  was  conducted  where  samples  were  exposed  to  1.354  milli hours/m 2 . Results indicate that storage in amber glass bottles is sufficie mercaptopurine  against  photo-degradation.  Nevertheless,  the  data  indicate  that prone to photodegradation. This is in accordance with the storage condition requirem monograph for mercaptopurine which states that it should be stored protected from se tailored to their varies.  An  in-use ld)  where  0.5ml  of ver a time span of ons, which mimics one  month  of  openings,  from  a  single  bottle  of  suspension.  As  the  study  was  conducted  over  an extended  period  of  time  the  suspension  was  subjected  to  a  maximum  challenge.  There  was  no of  the  preservative  system.  A summary of the data showed there was no loss of potency of mercaptopurine during the study and related  substances  remained  well  within  specification.  All  analytical  and  microbiological  parameters gical contamination remained at very low levels. In use, the patient dose is titrated so that every patient will be administered a do specific  response.  The  volume  of  suspension  drawn  up  by  each  patient  therefore stability  study  was  conducted  on  two  batches  of  suspension  (12  and  46  weeks  o Mercaptopurine Nova Laboratories suspension was withdrawn every working day o 42 days (6 weeks). This would ensure withdrawal of a typical volume on 30 occasi detectable  bioburden  at  the  end  of  the  study  confirming  the  efficacy remained within specification over the complete study. Microbiolo

eneral the results support the shelf-life and storage conditions as defined in the SPC. In g

## uct Comparability Exercise for Finished Medicinal Drug Prod

Not Applicable

## GMO

Not Applicable

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

## Quality Development

Information on development, manufacture and control of the active substance mercaptopurine and the oral  suspension has been presented in a satisfactory manner. The results of test carried out on the active  substance  and  the  drug  product  indicate  adequate  consistency  and  uniformity  of  important quality  characteristics  and  these  should  lead  to  a  satisfactory  and  uniform  performance  in  clinical practice.

<div style=\"page-break-after: always\"></div>

## 2.2.5.  Conclusions on the chemical, pharmaceutical and biological aspects

ith  the  conditions n the SmPC. Physicochemical and quality aspects relevant to the uniform performance of the product have been investigated and satisfactorily controlled. There is no concern related to the TSE The  quality  of  the  product  is  considered  acceptable  when  used  in  accordance  w defined i safety.

## 2.2.6. Recommendations for future quality development

The  applicant  should  investigate  the  possibility  to  eliminate  propyl-parahydroxybenzoate  from  the formulation  will  be  introduced  by  a  variation  as  detailed  in  the  Change ented by the applicant. formulation.  The  revised management protocol pres

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

been submitted and majority of literature data describing single city were reported in a publication (Clarke et al., 1953). As mercaptopurine is a well-known active substance, non-clinical studies have not the application was supported by a literature review. The dose and repeat dose toxi

The applicant received Scientific  Advice  from  the  CHMP  pertaining  to  the  non-clinical  aspects  of  the the need for non-clinical pharmacology or toxicology studies in relation in the 'to be marketed' formulation. dossier and more specifically to to the excipients intended to be used

## 2.3.2. Pharmacology

## Primary pharmacodynamics

nes. In vitro, the cytoxicity of 6-MP was investigated in several human leukaemia cell li

CEM  (T-cell acute d  Wilson  (Burkitt's rogressive increase sphate (TGMP) and d  over  80%  of  the Exposure  of Molt-4 (human  acute  lymphoblastic leukemia cell line),  CCRFlymphocytic  leukaemia  cell  line),  HL-60  (acute  myeloid  leukaemia  cell  line)  an lymphoma cell line), to 14C-6-MP (10 μ M) over a three hour period resulted in a p in the intracellular levels of TIMP (predominant metabolite), thioguanosine monopho 6-thioxanthine  monophosphate  (TXMP).  These  nucleotide  metabolites  represente total metabolites derived from 6-MP (Zimm S et al., 1985).

epletion of adenine y (Stet EH, 1995). In Molt F4 cells, exposure to mTIMP  reduces cell growth and viability, and the d nucleotides is thought to be an important contributor in mTIMP mediated cytotoxicit

GNs into DNA and cytotoxicity in mouse lymphoma L5178Y cell lines and Molt-4 cells have also been provided. In mouse lymphoma L5178Y cell lines, 0,4% replacement of guanine with TGN was associated with a 99,9% cell kill  rate  (Tidd  DM,  1974).  In  some  studies,  6-MP  has  been  shown  to  exhibit  classical  antimetabolite cytotoxicity profiles, with cell kill increasing as a function of both drug concentration and exposure time (Adamson PC et al., 1994). Other studies have found that delayed growth inhibitory effects following a 13 hour exposure time were only found for 6-MP concentrations of 25 -100 μ M (Tidd DM, 1974). Results of published studies investigating the relationship between incorporation of T

Moreover,  the  Applicant  has  provided  published  results  of  studies  investigating  the  relationship between incorporation of TGNs into DNA and cytotoxicity in  mouse lymphoma L5178Y cell lines and Molt-4  cells.  In  mouse  lymphoma  L5178Y  cell  lines,  0,4%  replacement  of  guanine  with  TGN  was associated with a 99,9% cell kill rate (Tidd DM, 1974).

In some studies, 6-MP has been shown to exhibit classical antimetabolite cytotoxicity profiles, with cell kill increasing as a function of both drug concentration and exposure time (Adamson PC et al., 1994).

<div style=\"page-break-after: always\"></div>

our  exposure  time Other  studies  have  found  that  delayed  growth  inhibitory  effects  following  a  13  h were only found for 6-MP concentrations of 25 -100 μ M (Tidd DM, 1974).

th cytotoxicity, and ons &gt;5 μ M were required for significant cell Similarly, for Molt-4 cells, prolonged exposure to 1 μ M 6-MP was not associated wi exposure times of greater than 8 h with 6-MP concentrati kill (Adamson PC et al.,1994). CCRF-CEM cells too have been shown to require &gt;48 hour exposure to 10 μ M 6-MP for any significant cytotoxic effect (da Silva et al., CP 1996).

been provided. In ded tumour growth xpansion death from 3 to 6 weeks compared to controls. (Clarke DA et al., 1953). activity of MP in altering the growth of a variety of mouse and ty in a variety of mouse cell leukaemias (Law LW, 1954; Burchenal JH, Results of in vivo studies investigating the anti-tumour potency of 6-MP have also mice implanted with S-180 tumours, a dose of 50 mg/kg of 6-MP significantly retar and delayed tumour-e Sugiura (Sugiura K, 1953) showed the rat tumours. 6-MP showed activi 1953; Law LW et al., 1954).

## Secondary pharmacodynamics

tted (see discussion on No studies or relevant information on secondary pharmacodynamics were submi non-clinical aspects).

## Safety pharmacology

e were submitted for ptopurine (see discussion on non-clinical aspects). No safety pharmacology studies and no relevant information from the literatur merca

## odynamic drug interactions Pharmac

mitted (see discussion on non-clinical No studies and no information from the literature were sub aspects).

## 2.3.3.  Pharmacokinetics

No non-clinical pharmacokinetic studies were submitted. Certain aspects of non-clinical etics have been described in the literature as detailed below. pharmacokin

## Absorption

iscussion on non-clinical No studies and no information from the literature have been submitted (see d aspects).

## Distribution

ng Pk et.al, 1983). MP in plasma and CSF had a mean half-life,lambda(z), hr/kg. In the postf 6-MP concentration from the CSF paralleled that from plasma. An in  vivo intravenous distribution study in the monkey has been reported (Nara Following a single intravenous dose of 6-MP, 6of 2.9 hours and an apparent volume of distribution (Vd,lambda(z) of 3.00 litres/ distributive phase, the decline o

## Metabolism

6-MP  is  a  pro-drug  and  therefore  requires  metabolism  before  being  able  to  exert  its  therapeutic cytotoxic effect. It is activated by hypoxanthine-guanine phosphoribosyl transferase (HGPRT), followed by extensive metabolism to TGNs, before being incorporated into the DNA and RNA. The main enzymes competing  for  the  initial  metabolism  of  6-MP  are  HGPRT,  thiopurine  methyltransferase  (TPMT), aldehyde oxidase (AO) and xanthine oxidase (XO). Both XO and AO produce metabolites believed to have little or no cytotoxic action (Coulthard S et al., 2005).

In  vivo  studies  in  rat  showed  6-MP  undergoes  a  high  rate  of  first-pass  metabolism  following  oral administration (Sasaki H et al., 1987).

<div style=\"page-break-after: always\"></div>

2 days (Innocenti F modulated  by  agents acting on enzymes of the purine metabolism, resulting in significant changes in erythrocytes and tissue levels of 6-mercaptopurine nucleotides (6-MPN) and the active 6-thioguanine nucleotides (6-TGN). In a study performed in rats after repeated administration of 6-MP by ip route for 1 et  al.,  1999),  6-MP  was  actively  metabolised.  6-MP  biotransformation  can  be

## Excretion

e published literature have been submitted (see discussion on No studies and no information from th non-clinical aspects).

## Pharmacokinetic drug interactions

with 6-MP caused a 2-fold  increase  in  the  half-life  and  AUC  of  6-MP,  a  2-fold  decrease  in  total  body  clearance  and  an approximate  3-fold  decrease  in  elimination  rate  constant.  Allopurinol  had  negligible  effects  on  the arameters  of  the  major  metabolite,  6-thiouric  acid,  suggesting  that  allopurinol serves to increase plasma levels of 6-MP by inhibiting its catabolism and thus contributing to a greater In vivo studies in rabbit showed that intravenous co-administration of allopurinol pharmacokinetic  p availability of 6-MP to the tissues (Tterlikkis L et Al., 1983).

## 2.3.4. Toxicology

ts from 1953 and 1954 ; Law LW 1954; LW et al., 1954) by the same groups that demonstrated its efficacy in mammalian tumours. All The pre-clinical toxicology of mercaptopurine was reported in published repor (Clarke DA et al., 1953; Philips FS et al., 1954; Sugiura K 1953; Burchenal JH 1954 Law data below come from these reports unless specifically stated otherwise.

## Single dose toxicity

Single dose toxicity studies were reported in the literature (Clarke DA et al., 1953). The LD 50 s of mercaptopurine in mouse, rat and cat by various routes of administration are provided in the following table.

Table 1: Summary of Single Dose Toxicity of mercaptopurine in various animal

## species

|       | Route ofAdministration Estimated LDsoinmg/kg   | Route ofAdministration Estimated LDsoinmg/kg   | Route ofAdministration Estimated LDsoinmg/kg   |
|-------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|       | Intravenous                                    | Intraperitoneal                                | Oral                                           |
| Mouse |                                                | 227                                            | 338                                            |
| Rat   |                                                | 225                                            | 382                                            |
| Cat   | >100                                           |                                                |                                                |

ty  following  single  high  doses  of mercaptopurine were similar in mice with mortality typically occurring 4 to 7 days after dosing, with animals  typically  appearing  normal  for  up  to  6  hours  after  dosing.  For  sub-lethal  doses,  transient bodyweight losses were noted for up to a week after dosing which were subsequently recovered during the  following  week.  Mortality  occurred  at  an  earlier  stage  in  rat,  with  the  majority  of  mortalities occurring within 24 to 48 hours of dosing. At these high doses, there were severe effects on respiration in rat which was not noted in mouse. Regardless  of  the  route  of  administration,  the  pattern  of  mortali

## Repeat-dose toxicity

The results of a repeated dose toxicity study performed in dogs and published in the literature have been provided (Clarke DA et al., 1953) as well as data from a small study in monkeys (Product Monograph Purinethol, Canada 2003). Results are summarised in the following table:

<div style=\"page-break-after: always\"></div>

: of re -dose studies provided by the Applicant Table 2  Summary peat toxicity

| Reference                                 | Species/Se Number/Group x/                                                        | Dose (mg/kg) /Route       | Duration                                                           | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------|-----------------------------------------------------------------------------------|---------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clarke et al, 1953                        | g/ g/day Do 10 mg/k : 4 animals 25 mg/kg/day : 4 animals 50 mg/kg/day : 2 animals | 10; 25 or 50 mg/kg/day IV | 10 mg/kg/day : 10 days mg/kg/day 25 : 4 days mg/kg/day 50 : 3 days | 10 mg/kg/day Weight loss, anorexia and evidence of bone testinal injury. (Recovery was s stopped). marrow and in rapid, when treatment wa 25 mg/kg/day Anorexia, weight loss, leucopenia sacrificed. The remaining 3 ery within 4 weeks of 1 of the 4 dogs was animals showed full recov cessation of the treatment. 50 mg/kg/day Vomiting within a few injection and blood and haemoconcentra hours after the 1st y diarrhoea, body weight loss tion. approximately 4 days tology showed denudation of the surface epithelium of the n and dilation of ndular nuclei, and on of the mucosa. ity of the bone marrow Occasional small areas of focal necrosis in the Animals became moribund after the last injection.and his intestine with congestio capillaries, atypia of gla leukocytic infiltrati Moderate  in the cellular liver. |
| Purinethol Monograph, Product Canada 2003 | Monkeys/2/ sex/group                                                              | 20; 40 or 80 mg/kg/day IV | 7 or 15 days                                                       | At all doses Moderate anorexia, slightly decreased activity and slight piloerection. Slight  BUN and serum transaminases nd red cell counts.  WBC count. ngs and kidneys.  in cell volume , Hb a Pathological changes in lu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Genotoxicity

As would be expected with a cytotoxic chemotherapeutic, mercaptopurine is clearly g vitro and in vivo. enotoxic both in

A number of genotoxicity studies have been reported in the literature. The Applicant has provided an al,  which  is  a  review  of  data  related  to  the  genetic  toxicology  of  6-MP. ts    have  been  observed  for  point  mutation  induction  ( S.  typhimurium )  and n  mammalian  cells induction of point change (SCE). [Mosesso P et al., 1993]. aberrations and in  germinal  cells. l., 1993]. article  of  Mosesso  P  et Consistent  positive  resul DNA  damage  in  bacteria  ( Bacillus  subtilis, E.  coli ).  [Mosesso  P  et  al.,  1993].  I cultured in vitro, including human hepatocytes, positive results were found for the mutations, chromosomal aberrations and sister chromatid ex In rodents treated in vivo, mercaptopurine clearly induced micronuclei, chromosomal SCEs  in  somatic  cells  and  dominant  lethals,  chromosomal  aberrations  and  SCEs However, mercaptopurine does not appear to be an inducer of aneuploidy. [Mosesso P et a

## Carcinogenicity

In the IARC monograph (1987), it is reported that 6-MP was tested by intraperitoneal administration in mice and by intraperitoneal, subcutaneous and intravenous injection in rats. Limitations to the data in all reports precluded evaluation of possible carcinogenicity of this compound.

A  2-year  carcinogenicity  study  published  in  the  literature  was  also  provided  to  document  the carcinogenic  potential  of  6-MP.  In  this  study  (Maekawa  A  et  al.,  1990),  mercaptopurine  was administered to F344 rats via the diet at dose levels of 0, 25 or 50 ppm for 2 years.

In males, there was no significant increase in the incidence of any tumour in the treated groups over that arising spontaneously in the control group.

In females, there were positive trends noted in the occurrence of several tumour types, including C-cell tumours,  pheochromotytomas,  uterine  adenocarcinomas  and  glioma,  with  the  incidence  of  C-cell

<div style=\"page-break-after: always\"></div>

higher  than  in  the tumours  and  pheochromocytomas  in  the  50  ppm  group  being  significantly concurrent control group.

Mercaptopurine is classified by the IARC as 'Group 3', meaning that the evidence of its carcinogenicity e, even if mercaptopurine is clearly genotoxic in vitro and in vivo. in humans is inadequat

## Reproduction Toxicity

The Applicant has provided an article by Mossesso et al (1993) which is an overview of all available ve data  on  6-mercaptopurine  including  studies  focusing  on  teratogenic,  embryotoxic  and  reproducti effects of the drug compond.

effects  of  chemotherapy  on  the  mouse  testis  found  that ls as evidenced e were some large y  shaped A study designed  to  evaluate  the mercaptopurine did not affect the viability of differentiated spermatogonia and stem cel by testicular sperm head counts on Days 29 and 56 of treatment. However, ther round  spermatids  which  were  presumed  to  be  diploid  and  a  high  frequency  of  abnormall elongated spermatids (Mosesso P et al., 1993).

oses not eliciting maternal toxicity. Mercaptopurine is embryotoxic in rodents at d was embryolethal /dose, respectively In one study mercaptopurine, administered as 2 doses on Days 7 and 8 of gestation, with 50% and 90% of foetuses being resorbed following doses of 5 or 10 mg/kg (Mosesso P et al., 1993) but no malformations were noted.

nd teratogenic effects induced by mercaptopurine in rats dosed on Days 7 and 12, respectively, were also reported (Mosesso P et al., 1993). Embryolethality a

00% death of embryos while lower doses (0.5-0.75 mg/kg) induced anomalies of the nervous system and the eyes. to 8 of gestation at Mercaptopurine, when administered to Wistar rats on Days 6-12 of gestation caused 1 Nervous system anomalies were also induced in Swiss Albino mice dosed on Days 6 doses of 0.5-1 mg/kg.

wiss  albino  mouse ouse on Day 11 of Limb malformations were seen in both rat  (dose  of  50  mg/kg  on  Day  12)  and  S (dose of 60 mg/kg on Day 11), with mandible malformations also observed in m gestation (dose of 60 mg/kg).

In rabbits, and in comparison to mouse and rat, far lower doses of 1 mg/kg were sufficient to induce severe limb malformations.

direct  lethal  effect  on  foetuses,  mercaptopurine  reduced  the  ability  of  the  surviving g  (F1  generation)  of  mice  to  reproduce  upon  reaching  maturity,  and  the  number  of ical  examination  of icles, reflecting the izes in the offspring. Malformations were observed in the second and P et al., 1993). In  addition  to  a female  offsprin foetuses  (live  and  dead)  per  pregnant  mouse  was  significantly  reduced.  Histolog ovaries from the F1 offspring revealed reduced numbers of oocytes and ovarian foll possible reason for small litter s third generation of offspring (Mosesso

## Local tolerance

transdermal  drug een  submitted  (see The  local  skin  irritation  properties  of  mercaptopurine  were  studied  as  part  of  a delivery  system.  No  non-clinical  studies  to  assess  oropharyngeal  toxicity  have  b discussion on non-clinical aspects).

## Other toxicity studies

## Immunotoxicity

The effects of mercaptopurine on immediate and delayed hypersensitivity were studied in the rabbit (Borel  Y,  et.  al,  1964).  Mercaptopurine  was  show  to  exert  both  central  and  peripheral  actions  on immune reactions. The central effects were inhibition of humoural antibody formation and suppression of  delayed  hypersensitivity.  Mercaptopurine  was  also  able  to  block  the  peripheral  manifestations  of immunity (skin reactions to antigens) without affecting the immune status of the animal. These various actions of mercaptopurine were brought out under selected conditions of timing, dosage and mode of antigen  administration.  The  processes  leading  to  the  development  of  delayed  hypersensitivity  were

<div style=\"page-break-after: always\"></div>

ent  being  able  to matory  responses. thor of the studies e due to an anti-inflammatory effect of mercaptopurine and inhibition of the local passive Arthus reaction (local type III hypersensitivity reaction) was a function of the amount of antibody in the test found  to  be  very  sensitive  to  the  effects  of  mercaptopurine,  with  4  days  treatm suppress  this  response  without  inhibiting  humoural  antibody  production  or  inflam The suppression of skin reactions in hyperimmunized rabbits is presumed by the au to b serum.

## Studies on impurities / excipients

## Hydroxybenzoate Preservatives

maceutical oic acids on OAEL (lowest observed adverse effect level) value of 12.4 mg/kg has been established for propyl-hydroxybenzoic acid (Johnson and Steer, 2005). The quantity of in this formulation is less than 0.25% of LOAEL at doses typically used in the mals it is not n particular to The proposed oral mercaptopurine suspension contains methylhydroxybenzoate and propyl-hydroxybenzoate in quantities that are usually recommended for phar formulations. There are numerous data addressing the effect of p-hydroxybenz spermatogenesis and a L propylhydroxybenzoate treatment of ALL. In the absence of toxicokinetic data and a sufficient number of ani possible to have a clear idea of the frequency of appearance of observed effects (i specify a threshold of toxicity).

## Xanthan gum (Xantual 75)

um (CAS No. 11138-66-2. E415) is a commonly used component of both pharmaceutical products and foodstuffs, having been extensively tested in animals and accepted as a food additive in nd USA. The Acceptable Daily Intake (ADI) given by the Food and Agricultural Organization of the United Nations and the World Health Organisation (FAO/WHO) Expert Committee on Food Additives nd tolerance, there is n. The amount of rmal for pharmaceutical Xanthan g Europe a (JECFA) is 'not specified' meaning that, on the basis of available data on safety a no limit for ADI and the gum may be used at a quantity suitable for its applicatio xanthan gum contained in the proposed mercaptopurine oral suspension is no formulations.

## Aspartame

AS No. 22839-47-0, E951) is an artificial non-saccharide sweetener which is a methyl both widely used as a ns as a sweetening agent. It is included in the proposed formulation with raspberry juice concentration to provide a palatable product to be acceptable to children and to help ensure patient compliance. The ADI values specified by the US FDA and the EFSA for aspartame are 50 mg/kg and 40 mg/kg bodyweight, respectively. The amount of aspartame contained in the proposed mercaptopurine suspension is less than 1% of the ADI. Aspartame (C ester of the dipeptide of the amino acids aspartic acid and phenylalanine. It is sugar substitute in food and beverages and used in pharmaceutical formulatio

## Raspberry juice

The concentrated raspberry juice is a well known and natural (non-synthetic) flavour with a high degree of acceptability.

<div style=\"page-break-after: always\"></div>

## sment 2.3.5. Ecotoxicity/environmental risk asses

esults Table 3: Summary of main study r

| (INN/ Nam rcaptopurine Substance Invented e): Me   | (INN/ Nam rcaptopurine Substance Invented e): Me   | (INN/ Nam rcaptopurine Substance Invented e): Me                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (INN/ Nam rcaptopurine Substance Invented e): Me   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| CAS-number (if available):                         | CAS-number (if available):                         | CAS-number (if available):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CAS-number (if available):                         |
| PBT screening                                      |                                                    | Result                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Conclusion                                         |
| Bioaccumulation potential- log K ow                | Publishe d                                         | rediction of Setschenow al of Pharmaceutics ,37 at pH 7,4 ska M, Hertman T, klewski J. Modeling of purine derivatives es based on their and quantum nal of Medicinal 2005) 48 (13) : 4482-4486]. = 0,01 at pH = 7,4 [Hazardous Substances Data Bank States. National Library of Medicine: Hansch C and Leo A. The Log P Database. Claremont, CA: = 0,71 [Ni N, Yalkowsky SH. P constants. International Journ (2003) 254: 162-172]. = - 0,17 at pH 5,7 and - 0 [Hoffman M, Chrzanow Rych transport across cell membran partition coefficient determination chemical calculations. Jour Chemistry ( of the United Pomona College 1987]. | < LogK ow 4.5 No potential PBT                     |
| Phase I                                            | Phase I                                            | Phase I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Phase I                                            |
| Calculation                                        | Value                                              | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Conclusion                                         |
| PEC surfacewater , refined                         | 0,00116                                            |  g/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |  0.01 threshold                                   |

An environmental risk assessment has been performed to evaluate the potential env the EU resulting from the us ironmental risk in e of 6-mercaptopurine monohydrate in Mercaptopurine Nova Laboratories mg/mLOral 20 mg/mLOral Suspension. Each 5 mL dose of Mercaptopurine Nova Laboratories 20 Suspension contains 100 mg 6-mercaptopurine monohydrate.

se  (DOSEai)  of  6opurine  can  be  considered  to  be  150  mg  (for  a  60  kg  adult  and  a  dose  of  2.5  mg/kg bodyweight per day). Based on estimations from published epidemiological data (assuming a 100% linical information, a refined value for market penetration (Fpen)  of  0.0000154  for  6-mercaptopurine  in  Mercaptopurine  Nova  Laboratories  20  mg/  mL  Oral For  the  purpose  of  this  environmental  risk  assessment,  the  maximum  daily  do mercapt market  share for child and adult ALL) and c Suspension has been  established.

ptopurine has been Using the refined Fpen value of 0.0000154, the PECSURFACEWATER values for 6 merca calculated to be 0.00116 μ g/L.

is &lt;4.5, such that persistence. ifiable  as  a  Persistent,  Bioaccumulative  and  Toxic  (PBT) substance. The log partition coefficient in octanol/water (log Kow) values of 6-mercaptopurine this  drug  substance  does  not  present  any  hazards  with  respect  to  bioaccumulation  and Therefore,  6-mercaptopurine  is  not  class

## 2.3.6. Discussion on non-clinical aspects

The  pharmacodynamic  properties  of  mercaptopurine  are  well-known  and  there  is  extensive  clinical experience with the compound. The Applicant provided a literature review of relevant non-clinical data. This  was  considered  acceptable  and  the  conduct  of  additional  animal  studies,  including  secondary pharmacology,  safety  pharmacology  and  pharmacodynamic  interaction  studies  was  not  considered necessary, as it would not add significantly to the existing knowledge. In terms of safety pharmacology it  should be noted that mercaptopurine is not associated with obvious adverse effects on behaviour, respiratory or cardiovascular endpoints in clinical use.

<div style=\"page-break-after: always\"></div>

d  but  due  to  the  extensive  clinical Data  on  the  pharmacokinetics  of  mercaptopurine  are  limite experience with mercaptopurine, the metabolism in humans is well understood.

ta published mostly ptopurine and that poietic system, the rat, mice, dog and severe respiratory ditis  and  pulmonary  lesions  were  reported  in  rats.  Generally, ce in which d th mercaptopurine. Overall, the toxicity profile is as expected for this class of compounds. Literature da in 1953 and 1954 have shown that there are no acute toxicities shown with merca mortality typically occurs 4-7 days after dosing. In general, disturbances in hemato gastrointestinal tract, and the liver were common findings in animal species tested ( monkey). Species specific side effects causing mortalities were also seen such as effects  in  rats.  Additionally  myocar mortalities occurred at earlier stages (24-48 hours of dosing) in rats when compared to mi mortalities occurred mostly 4-7 days after the dosing.  In both dog and monkey, recovery was rapi upon cessation of dosing wi itted.  The  lack  of e  extensive  clinical experience with mercaptopurine. No  specific  information  on  non-clinical  toxicokinetics  from  the  literature  was  subm toxicokinetic  information  from  animal  studies  is  considered  acceptable  given  th

c to reproduction, thus  no  additional As it has been established that mercaptopurine is genotoxic, carcinogenic and toxi the  safety  concerns  towards  mercaptopurine  have  already  been  identified  and testing in this regard is warranted.

er antimetabolites, vo in mice and rats. ytes  of  leukaemic captopurine and in As would be expected with a cytotoxic chemotherapeutic and in common with oth mercaptopurine is mutagenic and causes chromosomal aberrations in vitro and in vi Increases  in  chromosomal  aberrations  were  observed  in  the  peripheral  lymphoc patients, in a renal cell carcinoma patient who received an unstated dose of 6-mer patients with chronic renal disease treated at doses of 0.4 - 1.0 mg/kg/day.

higher incidence nomas and gliomas, and  the  incidences  of  C-cell  tumors  and  pheochromocytomas  in  the  highest  dose  group  were e total numbers of ost  of  the  tumors ns in this strain of ent. Nevertheless, and  in-vivo,  the pressed in  sections A 2 year oral (dietary) carcinogenicity study in rat showed positive trends towards a of certain tumours such as C-cell tumors, pheochromocytomas, uterine adenocarci significantly higher than the values in the respective control group. In addition, th malignant  tumors  increased  significantly  in  the  female  in  the  high  dose  group.  M showing high incidence in this study are frequently observed as spontaneous lesio rats, however the study is of insufficient quality to allow for an adequate assessm due  to  the  clear  genotoxic  potential  of  mercaptopurine  shown  both  in-vitro carcinogenic potential of mercaptopurine cannot be excluded. This is adequately ex 4.4 and 5.3 of the SPC.

ic in experimental animals at doses similar  or  greater  than  those  used  therapeutically  in  humans.  Increased  frequencies  of  fetal  death, s of mice, rats and t various times during organogenesis. In all species, the degree of embryotoxicity and estation  at  the  time  of mercaptopurine affected the ability of in the second and lity of differentiated mouse but did produce some large round spermatids (presumed text in section 4.6 eflect this information. 6-MP, in common with other cytotoxics, has shown to be teratogen central nervous system, facial and limb anomalies were observed among offspring rabbits treated a the  type  of  malformations  are  dependent  on  the  dose  and  stage  of  g administration. In addition to a direct lethal effect on foetuses, surviving female foetuses to reproduce upon reaching maturity and malformations third generation of offspring were reported. Mercaptopurine did not affect the viabi spermatogonia and stem cells in the to be diploid) and a high frequency of abnormally shaped elongated spermatids. The and relevant instructions in the package leaflet adequately r

No  juvenile  toxicology  studies  have  been  conducted  but  the  clinical  experience  in  this  regard  is considered sufficient.

The local skin irritation properties of mercaptopurine were studied as part of a transdermal drug delivery system. This study is however not relevant for the current application.

No non-clinical studies have been conducted to assess oropharyngeal toxicity. Given the long history of use of mercaptopurine and the extensive clinical database, the Applicant considers that the non-clinical assessment of local tolerance is unnecessary.

Oropharyngeal mucositis is considered unlikely to be influenced by local exposure to mercaptopurine, but will be influenced by systemic levels of TGN, the active metabolite.

<div style=\"page-break-after: always\"></div>

Mercaptopurine has been tested for skin irritation in mouse and human with 23 hour exposure per day for 21 days and shown to be non-irritant.

rmulation in an ral,  pharyngeal  and oesophageal  mucosa  and  peri-oral  skin  (due  to  accidental  spilling)  exposed  to  dissolved  drug  is intake of a tablet. According to the CHMP Scientific Advice given, data on local tolerance of the new fo adequate  animal  study  would  be  considered  of  relevance  since  the  surface  of  o expected to be considerably higher after intake of a liquid formulation than after Since these data were insufficient this issue is addressed in the clinical section.

eed  for  non-clinical used  in  the  'to  be in the formulation minimum without can be based on thorough literature research, considerations of the long term administration of the proposed drug product and CHMP also advised rahydroxybenzoate cordance  with  the and package leaflet of medicinal products for human use'. Scientific  advice  has  been  sought  by  the  Applicant  as  to  whether  there  is  a  n pharmacology  or  toxicology  studies  in  relation  to  the  excipients  intended  to  be marketed' formulation. The CHMP advised that the necessity of any excipient used has to be demonstrated and the content of all excipients should be restricted to a affecting the quality, safety and efficacy of the drug product. The discussion special emphasis on the intended use in children undergoing chemotherapy. The the applicant to discuss risk associated with the use of the preservatives propyl pa and  methyl  parahydroxybenzoate  at  the  proposed  long  term  treatment  in  ac Guideline on 'Excipients in the label wn and commonly nd  not  associated ves as esters of p -pylparaben)  in  the All of the excipients in the liquid formulation of mercaptopurine are considered kno included  as  food  additives  and/or  as  ingredients  in  pharmaceutical  formulations  a with toxicity, including any local tolerance effects. However, the choice of preservati hydroxybenzoic  acids  (parabens),  perhaps  especially  propylhydroxybenzoate  (pro paediatric populations is generally questioned.

4),  and  published ood  additives.  The l paraben  (propyl sis,  and  reduced mended for propyl paraben  was considered to be 1000 mg/kg/day. Parabens  are  known  to  have  oestrogenic  activity  (EFSA  scientific  opinion  200 available  toxicological  information  showed  uncertainties  regarding  parabens  as  f conclusion from  the expert panel was  that dietary administration of  propy hydrobenzoate)  induced  adverse  effects  (sperm  cells,  impaired  spermatogene testosterone) in male rats at dose levels of 10 mg/kg/day. No ADI could be recom paraben  because  of  the  lack  of  a  clear  NOAEL.  The  NOAEL  for  methyl  and  ethyl opulation should be ne  disrupting  properties.  However,  the  level  of  propyl  hydrobenzoate exposure for patients treated with Mercaptopurine Nova Laboratories is calculated by the Applicant to acknowledged the higher esters of ormulation  will  be the marketing authorization. Generally, the use of propyl hydrobenzoate in pharmaceuticals for the paediatric p avoided  because  of  its  endocri be less than 0.25% of the LOAEL which is considered to be low. The applicant has recommendations of the CHMP to minimize or eliminate the content of hydroxybenzoate  in  Mercaptopurine  Nova  Laboratories.  If  required,  a  revised  f introduced by variation of

t the typical doses ceptable and in line The content of aspartame in the liquid formulation of mercaptopurine is low and a prescribed for ALL will be less than 1% of the accepted daily intake (ADI). This is ac with the CHMP Scientific advice given.

tion  studies  in  the pigmented tissues are lacking. Normally, in these situations the lack of phototoxicity studies should be justified  but  due  to  the  extensive  clinical  experience  with  mercaptopurine  the  lack  of  photoxicity studies is considered acceptable. The  estimated  UVmax  for  mercaptopurine  seems  to  be  328nm  and  biodistribu

In  order  to  evaluate  the  potential  environmental  risk  in  the  EU  resulting  from  the  use  of  6mercaptopurine  monohydrate  in  Mercaptopurine  Nova  Laboratories  20  mg/  mL  Oral  Suspension,  an environmental risk assessment has been performed and submitted.

Based on estimations from published epidemiological data (assuming a 100% market  share for child and adult ALL) and clinical information, a refined value for market penetration (Fpen) of 0.0000154 for 6-mercaptopurine  in  Mercaptopurine  Nova  Laboratories  20  mg/  mL  Oral  Suspension  has  been established. This value is considerably lower than the default value of 0.01 in the CHMP Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00,

<div style=\"page-break-after: always\"></div>

CEWATER values for imes lower than the sessments  were  not eline. 01 June 2006). Using the refined Fpen  value of 0.0000154,  the PECSURFA 6-mercaptopurine has been calculated to be 0.00116 μ g/L. This value is nearly 10 t action  limit  of  0.01 μ g/L.  Therefore,  Phase  II  environmental  fate  and  effects  as considered necessary, which is acceptable and in line with the aforementioned guid vironment from the use of Mercaptopurine treatment of ALL, when used in accordance with nd the Package Leaflet. In conclusion, mercaptopurine is of negligible risk to the en Nova Laboratories 20 mg/ mL Oral Suspension for the the Summary of Product Characteristics (SmPC) a

## 2.3.7. Conclusion on the non-clinical aspects

ring this period, many thousands of children with ALL, throughout the world, have been administered 6-MP as part of a chemotherapy regimen. A great deal of understanding of the pharmacology and toxicology of the compound has therefore been acquired. No new preclinical data has been submitted for this new formulation of mercaptopurine and icient. 6-MP has now been used clinically for over 50 years. Du the literature data summarised by the applicant is considered suff

## r future pre-clinical development 2.3.8. Recommendation fo

s scussed in section 2.3.6. above, the use of parabens as excipients should be avoided. A  di ended  to the Applicant to investigate the possibility to eliminate propylm the formulation. The  CHMP  recomm parahydroxybenzoate fro

## 2.4. Clinical aspects

## 2.4.1. Introduction

ort  the  marketing cross-over  design assessment. This  is  an  application  for  oral  suspension  containing  mercaptopurine.  To  supp authorisation  application  the  applicant  submitted  one  bioequivalence  study  with under fasting conditions. This study was the pivotal study for the rmacodynamics as The applicant provided a clinical overview outlining the pharmacokinetics and pha well as efficacy and safety of mercaptopurine based on published literature.

mal  scientific  advice  was  given  on  clinical  aspects  by  the  CHMP  for  this  medicinal  product.  The mission of only bioequivalence data to support the clinical aspects of this application is in line with of Bioequivalence For sub this Scientific Advice. For the clinical assessment, the Guideline on the Investigation (CPMP/EWP/QWP/1401/98 Rev.1 ) in its current version is of particular relevance.

rovided unlicensed d formulation of In certain EU countries such as the UK, manufacturers of so called 'specials' have p liquid formulations of 6-MP for some time, including the currently applie Mercaptopurine Nova Laboratories.

## GCP

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

The bioequivalence clinical study was performed at AddClin Research (Pty) Ltd., Pretoria, South Africa. The study was monitored by Shandon Clinical Trials Ltd, Cork Ireland. The applicant has provided a statement  to  the  effect  that  the  study  was  conducted  in  accordance  with  South  African  law,  the European  Clinical Trials Directive (2001/20/EC),  the ICH  Guideline for Good  Clinical Practice (CPMP/ICH/135/95, January 17, 1997) and the Declaration of Helsinki Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

nes Control Council y  2010  (Pending). Shandon Clinical  Trials  has  been  audited  by  the  Irish  Medicines  Board  (IMB)  most  recently  in  2004 External audits : The clinical site (AddClin in South Africa) was audited by the Medici of  South  Africa  (MCC)  in  November  2005,  November  2007  and  on  21  -  23  Jul (GCP), 2007 (GMP) and 2010 (GCP).

a  GLP  compliance al laboratory (GBN P  compliance  were representative)  at 009)  and  at  Parexel  (Pty)  Ltd.  (Aug  7,  2009).  Triclinium  performed various monitoring visits at AddClin during the course of the clinical phase of the study. The statistics e Shandon Clinical Trials Ltd. Quality Assurance unit, which also checked the Internal audits :  The  study  report  informs  that  on behalf  of  Nova  Laboratories  Ltd audit on 18 Aug, 2009 was performed by Triclinium (a private CRO) at the analytic Analytics  -  division  of  Parexel  (Pty)  Ltd.,  South  Africa).  Pre-study  audits  for  GC performed  by  Shandon  Clinical  Trials  (accompanied  by  the  Nova  Laboratories AddClin  Research  (Aug  4-5,  2 were quality assured by th study final report according to ICH GCP.

## 2.4.2.   Pharmacokinetics

acokinetic  properties  of  6-mercaptopurine  tablet  formulation  are  well  known  out  of  the experience  with  Puri-Nethol  50  mg  tablets  and  are  summarised  below.    A  bioequivalence  study as a basis for this The  pharm intended to bridge the existing data with the new liquid formulation was submitted application.

## Absorption

ract.  However,  the bility is lower due to high first-pass metabolism, which is also subject to large in  children,  with  a About  50%  of  an  oral  dose  of  6-MP  is  suggested  to  be  absorbed  from  the  GI  t absolute oral bioavaila inter-individual  variation.  A  mean  oral  bioavailability  of  16%  has  been  reported range from 5 to 37%.  The mean Tmax is 2.2 hours with a range of 0.5 to 4 hours.

d after intravenous . However, 6-MP is ave a longer half6-MP disappears rapidly from plasma, with t1/2 values of 20 to 90 minutes reporte administration. Generally, no parent compound is detected in plasma 8 hr after dose activated intra-cellularly by conversion to cytotoxic ribonucleotide derivates, which h life (approximately 5 hours).

nd oxidation as well ed via tiopurine c polymorphism. In a  Caucasian population approximately 89% have normal enzyme activity, 11% intermediate activity leads  to  a  high associated with ine  oxidase  and  is unchanged  parent In the liver, mercaptopurin is rapidly and extensively metabolised by methylation a as the formation of inorganic sulfates. S-metylated metabolites are form methyltransferase (TPMT). TPMT activity is highly variable in patients due to geneti and  0.3%  low  or  non-detectable  activity.  On  chronic  dosing,  low  TPMT  activity accumulation of 6-thioguanine nucleotides in erythrocytes, which has been myelosuppression.  The  inactive  metabolite  6-thio  uric  acid  is  formed  via  xanth excreted  in  urine.  About  7%  of  an  oral  dose  has  been  reported  to  occur  as compound in urine within 12 hours.

lso subject to large children,  with  a to 37%.  The mean Tmax is 2.2 hours with a range of 0.5 to 4 hours. The absolute oral bioavailability is low due to high first-pass metabolism, which is a inter-individual  variation.  A  mean  oral  bioavailability  of  16%  has  been  reported  in range from 5

ildren. In one study, administration of mercaptopurine 15 minutes after a standard breakfast including milk delayed Tmax and reduced the AUC and Cmax by 26% and 36%, respectively. However, in another study a high inter-individual  variation  was  seen,  but  no  clear  effect  of  a  breakfast  consisting  of  milk  or  yoghurt, cereal and sandwiches, on mercaptopurin bioavailability. Yet another study showed a not statistically significant decrease in AUC and/or Cmax by 20-22% after a standardised breakfast, again with a wide inter-individual  variation. In  vitro data  indicate  that  mercaptopurine  is  catabolised  in  cow's  milk, suggested due to the presence of the mercaptopurine-metabolising enzyme xanthine oxidase which is present in milk. The Stockley's drug interaction database reports three food interaction studies in ch

The Applicant  presented  a  case  report  (Sofianou-Katsoulis et  al ,  2006)  of  a  patient  who  during  the maintenance phase had elevated peripheral blood counts despite increasing the 6-MP dose to 160% of the calculated dosage for his body surface area (BSA). It was found out that the boy routinely took the

<div style=\"page-break-after: always\"></div>

uced to the normal ed bioavailability of idase in 6-MP. 7 º C for 30 minutes for 5 minutes. In a ion of 6-MP with a ilk, reduced AUC by about 27%. In a study by Lonnerholm et al , 1989, on  the  other  hand,  there  was  no  difference  in  the  mean  bioavailability  of  6-MP  when  taken  with breakfast compared with the fasted state (mean ratio 1.03) but the individual fed/fasted ratios varied considerably, between 0.33 and 1.81. chemotherapy with cow's milk. After changing to water, the 6-MP dose could be red dose (100% of the calculated dose for his BSA). The authors suggest that the reduc 6-MP at administration with cow's milk could be due to the high content of xanthine ox Rivard et al , 1989, showed that incubation of 6-MP with pasteurised cow's milk at 3 resulted in 30% catabolism of 6-MP.  There was no effect if the milk was boiled study in 17 children with ALL, Riccardi et al ,  1986, demonstrated that administrat breakfast, including 250 ml m

## Bioequivalence

## alence study (SC02808) Clinical bioequiv

port of the application, one original clinical study report has been submitted. The primary ive of the study was 'to evaluate the pharmacokinetic characteristics and compare the ty of a Test formulation (Mercaptopurine Oral Suspension 100 mg/5 ml) and the marketed ation (Puri-Nethol 50 mg Tablet) using a single-dose, randomised, two-period In sup object bioavailabili Reference formul crossover design'.

## Methods

## Study design

se crossover study ght fast, subjects i-Nethol tablet (reference) or 2.5 ml of the 6-MP oral suspension 20 mg/mL(test). Subjects were not served any food until 4.5 hours after the dose. Blood-samples were at 0.25, 0.5, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0 and iod of at 2009, at nical study was sponsored by Nova laboratories Ltd. The analytical part of the study was conducted between Nov 25 and Dec 7, 2009, at Parexel Bioanalytical Services Division, uth Africa. The study was a randomised, two-treatment, two-period, two-sequence single-do conducted in 60 male, healthy volunteers under fasting conditions. After an overni were dosed with either one 50 mg Pur collected pre-dose and 12.0 hours after drug administration. The study periods were separated by a wash-out per least 72 hours. The clinical part of the study was conducted between Sept 25 and Oct 7, AddClin Research (Pty) Ltd., Pretoria, South Africa.  The study was monitored by Shandon Cli Trials Ltd, Cork Ireland. The Mosselbay, So

## Test and reference products

100 mg/5ml, manufactured by Nova Laboratories Ltd. Leicester, UK, batch No. 0790W001, expiry date: Oct 6, 2009. Test product: Mercaptopurine oral suspension,

Puri-Nethol,  50  mg  tablet,  manufactured  by  GlaxoSmithKline,  UK,  batch  No. ec 31, 2013. Reference  product: 902797, expiry date: D

## Population studied

The study was conducted in healthy, male volunteers. A total of 60 adult healthy volunteers were to be enrolled.    Dropouts  were  to  be  replaced  if  the  number  of  subjects  completing  the  study  would otherwise be less than 60. However, there were no drop-outs and all 60 subjects completed both study periods and were included in the pharmacokinetic analysis.

## Analytical methods

Plasma samples were stored at -70ºC in the clinic until shipped to the analytical laboratory. Plasma concentrations of mercaptopurine were determined with a validated LC/MS/MS method. 6-thioguanine was used as internal standard. Altogether, 1920 plasma samples from 60 volunteers were analysed.

<div style=\"page-break-after: always\"></div>

## Pre-study validation

purine.  The  lowest 5 ng/mL. A dilution could be analysed ty of analyte peak areas was observed in on so The  validation  range  for  mercaptopurine  was  0.508  -  128  ng/ml  for  6-mercapto recorded concentration of mercaptopurine was 0.5 ng/mL and the highest was 25 test showed that concentrations of up to 205 ng/ml of 6-mercaptopurine in plasma reliably when diluted into the calibration range. High variabili the presence of haemolysed blood (1 %). The internal standard provided sufficient compensati that the precision of the peak area ratios was well within acceptance criteria.

nsitivity at the limit of ml, was shown. Satisfactory between- and within-run accuracy and precision was demonstrated. e-thaw cycles. Specificity was shown employing 6 independent sources of human plasma. Se quantification, 0.508 ng/ was shown for low, medium and high QC sample concentrations. Dilution integrity Stability in plasma was demonstrated for 6 h at room temperature, and over 3 freez

## Within-study validation

th analysis of study samples.  The  validation  range  for  mercaptopurine  was  0.497  ng/ml  -  130  ng/ml.    Specificity  was k plasma from six sources. Recovery was 87%, 86% and 84% for high, medium and low QC samples, respectively. Satisfactory method performance during study sample analysis was analysis  was  adequately The assay method was subject to partial re-instatement validation in connection wi demonstrated in blan demonstrated.  Appropriate  batch  acceptance  criteria  were  used.  Repeated justified.

## Pharmacokinetic Variables

ntal methods.  The Pharmacokinetic variables were calculated using conventional non-compartme primary pharmacokinetic variables were Cmax, AUC0-t and AUC0-∞ .

## Statistical methods

o compare the pharmacokinetics of the two products, ANOVA was used on log-transformed AUC , AUC , and C and 90% that the oral intervals for the 0-t and Cmax. The statistical analysis was performed at Shandon Clinical Trials Ltd. T 0-t 0- max confidence interval for the test/reference ratio were calculated. The protocol stated suspension and the tablet were to be concluded bioequivalent if the 90% confidence test/reference ratio of the population geometric means fell within 80-125% for AUC

## Results

oki esults of udy are presented in Ta gure 1below. The pharmac netic r the st ble 4and Fi

The extent of exposure (AUC) and the peak concentratio were approximately 13% and 40% er, respe he sio he ta The absorption rate was higher for the suspension, with a point estimate for Tmax ratio (suspen blet) of 0.48 (90% CI:s 0.28-0.61). n (Cmax) high ctively, for t oral suspen n than for t blet. sion vs. ta

tic s, 808 Table 4: Ph armacokine parameter study SC02

| Treatment                                                                                                                                                                                                                                          | AUC 0-t ng*h/ml                                                                                                                                                                                                                                    | AUC 0- ∞ ng*h/ml                                                                                                                                                                                                                                   | C max ng/ml                                                                                                                                                                                                                                        | t max h                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suspension                                                                                                                                                                                                                                         | 121.64 ± 36.70                                                                                                                                                                                                                                     | 123.31 ± 37.15                                                                                                                                                                                                                                     | 86.63 ± 39.65                                                                                                                                                                                                                                      | 0.75 (0.25 - 2.50)                                                                                                                                                                                                                                 |
| Tablet                                                                                                                                                                                                                                             | 109.39 ± 43.19                                                                                                                                                                                                                                     | 11.92 ± 43.09                                                                                                                                                                                                                                      | 68.99 ± 47.49                                                                                                                                                                                                                                      | 1.67 (0.50 - 5.00)                                                                                                                                                                                                                                 |
| *Ratio suspension/tablet (90% CI)                                                                                                                                                                                                                  | 114.10 107.92 - 120.64                                                                                                                                                                                                                             | 112.65 106.63 - 119.02                                                                                                                                                                                                                             | 139.07 122.39 - 158.03                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                  |
| AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0- ∞ area under the plasma concentration-time curve from time zero to infinity C max maximum plasma concentration t max time for maximum plasma concentration | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0- ∞ area under the plasma concentration-time curve from time zero to infinity C max maximum plasma concentration t max time for maximum plasma concentration | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0- ∞ area under the plasma concentration-time curve from time zero to infinity C max maximum plasma concentration t max time for maximum plasma concentration | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0- ∞ area under the plasma concentration-time curve from time zero to infinity C max maximum plasma concentration t max time for maximum plasma concentration | AUC 0-t area under the plasma concentration-time curve from time zero to t hours AUC 0- ∞ area under the plasma concentration-time curve from time zero to infinity C max maximum plasma concentration t max time for maximum plasma concentration |

<div style=\"page-break-after: always\"></div>

ne in plasma against time following a single dose of Treatment A (suspension) and Treatment B (tablet) Figure 1: Plot of the mean concentration of mercaptopuri

<!-- image -->

The inter-subject variability was lower for the suspension (treatment A) than for the tablet (treatment B), as can be seen in Table 5.  More specifically, the inter-individual CVs for AUC were 30% and 39% for the suspension and for the tablet, respectively. The inter-subject variation in Cmax was 46% for for the tablet. Also the Cmax range was narrower for the suspension, 37.7 55 ng/ml for the tablet. As a result, the lowest as well as the highest Cmax detected was for the tablet (Figure 2a and b). the suspension and 69% 212 ng/ml vs.  6.72 - 2

Table 5: Inter-individual CVs fro Cmax, AUC0-t, AUC0-∞ and Tmax

|                    | Cmar   | Cmar   | AUCo   | AUCo   | AUC..   | AUC..   | Tma    | Tma    |
|--------------------|--------|--------|--------|--------|---------|---------|--------|--------|
|                    | A      | 8      | A      | B      | A       | B       | A      | B      |
| Inter-subject CV % | 45.77% | 68.83% | 30.17% | 39.48% | 30.13%  | 38.50%  | 51.40% | 66.19% |

treatment A = suspension, test treatment B = tablet, reference

<div style=\"page-break-after: always\"></div>

ions of mercaptopurine in plasma against time following a single dose of Treatment A (oral suspension) Figure 2a: Overlaid plots of individual concentrat

Individual plasma concentration graphs for Treatment A

<!-- image -->

Time (in hour s )

Figure 2b: Overlaid plots of individual concentrations of mercaptopurine in plasma against time following a single dose of Treatment B (tablet)

Individual plasma concentration grophs for Treatment B

<!-- image -->

## Elimination

6-MP disappears rapidly from plasma, with t1/2 values of 20 to 90 minutes reported after intravenous administration. Generally, no parent compound is detected in plasma 8 hr after dose. However, 6-MP is activated intra-cellularly by conversion to cytotoxic ribonucleotide derivates, which have a longer halflife  (approximately  5  hours).  The  active  6-MP  ribonucleotides  are  formed  via  hypoxantin  guanine phosphoribosyl  transferase  in  a  step-wise  process.  6-MP  ribonucleotide  inhibits  purine  nucleotide synthesis and metabolism which in turn alters the synthesis and function of RNA and DNA.

In  the  liver,  mercaptopurine  is  rapidly  and  extensively  metabolised  by  methylation  and  oxidation  as well  as  the  formation  of  inorganic  sulfates.  S-metylated  metabolites  are  formed  via  tiopurine methyltransferase (TPMT). TPMT activity is highly variable in patients due to genetic polymorphism. In a Caucasian population, approximately 89% have normal enzyme activity, 11% intermediate activity and  0.3%  low  or  non-detectable  activity.  On  chronic  dosing,  low  TPMT  activity  leads  to  a  high

Time (in hours)

<div style=\"page-break-after: always\"></div>

associated with ine  oxidase  and  is excreted  in  urine.  About  7%  of  an  oral  dose  has  been  reported  to  occur  as  unchanged  parent compound in urine within 12 hours. accumulation of 6-thioguanine nucleotides in erythrocytes, which has been myelosuppression.  The  inactive  metabolite  6-thio  uric  acid  is  formed  via  xanth

## ulations Special pop

There  are  no  specific  studies  on  the  pharmacokinetics  or  safety  of  6-MP  in  patients  with  renal  or hepatic impairment.

## 2.4.3. Pharmacodynamics

acology). No new pharmacodynamic studies were presented (see discussion on clinical pharm

## 2.4.4. Discussion on clinical pharmacology

lability  of  oral  6sults  from  its  firstiatric  patients,  the The  pharmacological  profile  of  6-mercaptopurine  is  well  known.  The  bioavai mercaptopurine  shows  considerable  inter-individual  variability,  which  probably  re pass  metabolism.  When  administered  orally  at  a  dosage  of  75 mg/m 2 to 7 paed bioavailability averaged 16% of the administered dose, with a range of 5 to 37%.

tent and based on the variability observed (in published literature data) it is suggested that the main concern might be nted data, it might endations to avoid the product information. Since drug ration in the fasted state may  be  difficult, especially in small children, appropriate ised with regard to in the SPC. This is atological response. Data on the effect of food on mercaptopurine bioavailability appears to be inconsis milk products, since these contain xanthine oxidase. Although, based on the prese be difficult to discern the effect of food in general from the effect of milk, recomm concomitant intake of milk products were included in administ recommendation that for the individual patient, administration should be standard concomitant food, but that concomitant milk products should be avoided is included considered adequate, given that the dose will be individually titrated based on haem divergent  results  of  food  interaction  studies,  and  that  administration  in  the  fasted  state been introduced in Given  the might be difficult, especially in small children, the following recommendations have the Summary of product Characteristics and reflected in the Package Leaflet:

## Section 4.2:

ine  Nova  Laboratories  may  be  taken  with  food  or  on  an  empty  stomach,  but  patients should  standardise  the  method  of  administration.  The  dose  should  not  be  taken  with  milk  or  dairy least 1 hour before Mercaptopur products (see section 4.5).  Mercaptopurine Nova Laboratories should be taken at or 2 hours after milk or dairy products.

## Section 4.5 :

The administration of 6-mercaptopurine with food may decrease systemic exposure slightly but this is unlikely to be of clinical significance. Therefore, Mercaptopurine Nova Laboratories may be taken with food or on an empty stomach, but patients should standardise the method of administration. The dose should not be taken with milk or dairy products since they contain xanthine oxidase, an enzyme which metabolises  6-mercaptopurine  and  might  therefore  lead  to  reduced  plasma  concentrations  of mercaptopurine.

The  available  evidence  suggests  administration  of  mercaptopurine  in  the  evening  results  in  greater efficacy and hence reduced risk of relapse, therefore the optimal time of the day for Novapurine intake is in the evening. The following wording is included in section 4.2:

<div style=\"page-break-after: always\"></div>

ministration  in  the tration may lower the risk of relapse. Therefore the daily dose of Mercaptopurine  displays  diurnal  variation  in  pharmacokinetics  and  efficacy.  Ad evening compared to morning adminis Novapurine should be taken in the evening

As there are no specific studies on the pharmacokinetics or safety of 6-MP in patients with renal or hepatic impairment, the SPC recommends caution in these populations.

c agents in healthy considered the use ate occasions only, e human body are vary  from  1.5  -  5 dose  will  be  105 an oral suspension t each of the two dosing visits with a washout period of at least 3 days between visits. The ny short- or longped  for  thiopurine ivity were recruited The bioequivalence study was conducted in healthy volunteers. Testing of cytotoxi volunteers is considered problematic from the ethical point of view. The Applicant of healthy volunteers as justified since a single dose was administered on two separ while studies in humans and animals have indicated that the effects of 6-MP on th caused  by  chronic  administration.  In  childhood  and  adult  leukaemia,  doses mg/kg/day  (continuously).  Thus,  in  an  adult  male  weighing  70  kg  the  minimum mg/day. In this study, volunteers were given a single 1 x 50 mg dose of 6-MP (as or tablet) a relatively low dose and the dosing schedule was suggested to minimise the risk of a term  toxicity  from  two  doses  of  6-MP.  Furthermore,  subjects  were  phenoty methyltransferase (TPMT) activity. Only subjects with normal or high enzyme act into this study.

hy volunteers (e.g. thorisation application. However, since 6-MP is an antie  number  of  adult There have been cases where bioequivalence studies have been conducted in healt generic versions of 6-MP and azathioprine -a pro-drug of 6-MP tablets) and this approach has been considered acceptable as part of a Marketing Au purine  metabolite  with  a  significant  toxicity  profile,  it  was  appropriate  to  limit  th healthy volunteers recruited as part of the bioequivalence study.

as  justified  since nd children without The  Applicant  suggested  that  use  of  adult  instead  of  paediatric  volunteers  w 6-mercatopurine as Puri-Nethol (the reference formulation) is used in both adults a any difference in dosing, which is given on a mg/m 2 basis.

f different 6-MP pose  a  number  of There are no data to suggest that age is likely to influence the performance in vivo o formulations  and  hence  absorption.  A  bioequivalence  study  in  children  would significant challenges:-

- edications  such  as -  The  ALL  population  is  heterogeneous  with  significant  covariates  (e.g.  co-m methotrexate) which could influence the rate and extent of 6-MP absorption.
- continuation phase se of therapy, the t  counts.  Thus,  the iples of) 50mg Puri-Nethol tablet(s) will be extremely limited and present a significant challenge. For the majority of children, the 50mg tablet the Section 6, this herefore may bias - The dosing is individualised; 6-MP is initiated at a dose of 75mg / m 2 during the of ALL treatment (i.e. according to the child's body surface area). During the cour dose  is  individualised  for  each  child  according  to  absolute  neutrophil  and  platele possibility of recruiting children that are taking a single (or mult is split to achieve as near as possible to the desired dose. As already mentioned in can result in administering a dose which varies significantly from that intended and t the trial outcome.

acokinetics  In  The EMEA/CHMP/EWP/ inical  documentation  between  two adults,  since  the  applicant can justify that the study lthy volunteers was Moreover,  it  is  recognised,  that  according  to  'Guideline  On  The  Role  Of  Pharm Development  Of  Medicinal  Products  In  The  Paediatric  Population'  (Doc.  Ref. 147013/2004),  bioequivalence  studies  for  bridging  paediatric  cl formulations should preferably be performed in results can be extrapolated to the paediatric population. Hence the inclusion of hea considered acceptable provided the risks are acceptable for healthy volunteers.

The  results  indicated  that  the  extent  of  exposure  (AUC)  and  the  peak  concentration  (Cmax)  were approximately 13% and 40% higher, respectively, for the oral suspension than for the tablet, although the  90%  confidence  interval  for  the  AUC  ratio  fell  within  the  normally  applied  limits  for  concluding bioequivalence between two products. The absorption rate was clearly higher for the suspension, with a  point  estimate  for  Tmax  ratio  (suspension  vs.  tablet)  of  0.48  (90%  CI:s  0.28-0.61).  Cmax  is approximately 40 % higher with the suspension and therefore switch from tablet to liquid should be done with caution.  The following statement is included in section 4.2 of the SmPC:

## Switching between tablet and oral suspension and vice versa

A tablet form of 6-mercaptopurine is also available. The 6-mecaptopurine oral suspension and tablet are not bioequivalent with respect to peak plasma concentration, and therefore intensified haematological monitoring of the patient is advised on switching formulations (see section 5.2).

<div style=\"page-break-after: always\"></div>

netic profile between the suspension and the tablet was described in the The difference in pharmacoki SmPC, section 5.2, as follows:

of  Novapurine oral UC, but not Cmax. her than the tablet n (46%) than the imination  half-life  of  6-mercaptopurine  is  90  ±  30  minutes,  but  the  active The apparent topurine  into the 'In  a  comparative  bioavailability  study  in  healthy  adult  volunteers  (n=60),  50mg suspension was demonstrated to be bioequivalent to the reference 50mg tablet for A The mean (90% CI) Cmax with the oral suspension was 39 % (22% - 58%) hig although there was less between-subject variability (%C.V) with the oral suspensio tablet  (69%). 'The  el metabolites have a longer half-life (approximately 5 hours) than the parent compound. body  clearance  is  4832 ± 2562  ml/min/m 2 .  There  is  low  entry  of  6-mercap cerebrospinal fluid.

lar anabolism of 6ucleotides (TGNs), tep is  catalysed by sphate  (TIMP).  6transferase (TPMT), e S-methylation of le  nucleotide  metabolite,  TIMP,  to  form  methylthioinosine  monophosphate  (mTIMP).  Both e, an enzyme which is ic enzyme and it converts is  excreted  in  the  urine. within 12 hours after The main route of elimination for 6-mercaptopurine is by metabolism. The intracellu merpactopurine is catalysed by several enzymes to eventually form 6-thioguanine n but a variety of intermediary TGNs are formed en route to the TGNs. The first s hypoxanthine-guanine  phosphoribosyl  transferase  yielding  thioinosine  monopho mercaptopurine is also subject to S-methylation by the enzyme thiopurine S-methyl yielding methylmercaptopurine, which is inactive. However, TPMT also catalyses th the  princip TIMP and mTIMP are inhibitors of phosphoribosyl pyrophosphate amidotransferas important in de novo purine synthesis. Xanthine oxidase is the main catabol the  6-mercaptopurine  into  the  inactive  metabolite,  6-thiouric  acid.  This Approximately 7% of an oral dose is excreted as unchanged 6-mercaptopurine administration.

tivity who are very sensitive ould be exacerbated by coadministration with active substances that inhibit TPMT, such as olsalazine, ough these tests e monitoring of enerally required for homozygous-TPMT ssion. There are individuals with an inherited deficiency of the TPMT enzyme ac to the myelosuppresive effect of 6-mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6-mercaptopurine. This problem c mesalazine or sulfasalazine. Some laboratories offer testing for TPMT deficiency, alth have not been shown to identify all patients at risk of severe toxicity. Therefore clos blood counts is necessary. Substantial dose reductions are g deficiency patients to avoid the development of life threatening bone marrow suppre and myelodysplasia mbination with other cytotoxics A possible association between decreased TPMT activity and secondary leukaemias has been reported in individuals receiving 6-mercaptopurine in co

n, when given with ised Ratio) value is In terms of other drug interactions, inhibition of the anticoagulant effect of warfari 6-mercaptopurine, has been reported. Monitoring of the INR (International Normal recommended during concomitant administration with oral anticoagulants.

ents  may  decrease  the  intestinal  absorption  of  phenytoin.  Careful  monitoring  of  the phenytoin serum levels is recommended. It is possible that the levels of other anti-epileptic medicinal tic levels should be closely monitored during treatment dose adjustments as necessary. Cytotoxic  ag products may also be altered. Serum antiepilep with Mercaptopurine Nova Laboratories, making antly it is essential n since allopurinol decreases  the  rate  of  metabolism  of  6-mercaptopurine    via  xanthine  oxidase.  Also  other  xanthine oxidase  inhibitors,  such  as  febuxostat,  may  decrease  the  metabolism  of  mercaptopurine  and concomitant  administration  is  not  recommended  as  data  are  insufficient  to  determine  an  adequate dose reduction. When allopurinol and Mercaptopurine Nova Laboratories are administered concomit that only a quarter of the usual dose of Mercaptopurine Nova Laboratories is give

## 2.4.5. Conclusions on clinical pharmacology

In  conclusion,  the  results  of  the  submitted  comparative  bioavailability  study  indicate  that  the bioavailability  from  the  suspension  is  in  the  same  range  as  for  the  tablet,  since  bioequivalence  was demonstrated  for  AUC,  i.e.  extent  of  absorption.  The  suspension  also  appears  to  perform  more

<div style=\"page-break-after: always\"></div>

tablet. The rate of absorption was higher for the suspension than for the tablet, predictable than the leading to a higher Cmax.

The pharmacokinetic data are considered sufficient for a new pharmaceutical form.

ension has reliable etics.  The  liquid  product  should  also  enable  more  precise  dosing.  These  two  factors more  predictable  dosing  on  an individual basis. It is concluded that the pharmacokinetic study shows that the Novapurine oral susp pharmacokin (reliable  pharmacokinetics  and  precise  dosing)  should  facilitate

Pharmacology issues discussed are appropriately reflected in the product information.

## 2.5. Clinical efficacy

ubmitted. Reference to literature data and experience with the ach is in compliance with the CHMP Scientific Advice. No new clinical efficacy data have been s Puri-Nethol tablet was made.  This appro

## 2.5.1. Discussion on clinical efficacy

phase, followed by Although 6-MP may ontinuation phase. aptopurine and weekly methotrexate constitutes the basis of most continuation regimens. utcome. The basic approach to ALL therapy consists of a relatively brief remission-induction intensification (consolidation) treatment and then prolonged maintenance therapy. be administered during intensification (consolidation), its main use is during the c Daily merc This combination given to the limits of tolerance is associated with improved clinical o s), the reasons for chemotherapy (to ere may be a subnt  to  identify  them Although all children with ALL require prolonged continuation therapy (2 - 2.5 year this are not well defined. However, decreasing the duration of continuation phase of 12 - 18 months) produced worse outcomes (event free survival) overall. While th group of children who do not need prolonged therapy, it is not possible at prese prospectively.

e  potent  than  mercaptopurine  in  model  systems  and  leads  to  higher cerebrospinal  fluid drugs Thioguanine, emic  responses  to ith  profound  thrombocytopenia,  an  increased  risk  of  death  in sease. Although the d liver damage, this of choice for acute courses  during  the Since  thioguanine  is  mor concentrations  of  thioguanine  nucleotides  in  cells  and  cytotoxic  concentrations  in several randomised trials have been done to compare the effectiveness of these two given  at  a  daily  dose  of  40  mg/m²  or  more,  produced  superior  anti-leuka mercaptopurine  but  was  associated  w remission, and an unacceptably high rate (10-20%) of hepatic veno-occlusive di lower activity of thiopurine methyltransferase is associated with thioguanine-relate measure cannot identify reliably patients at risk 6-MP, therefore, remains the drug lymphoblastic leukaemia, although thioguanine could still be given in short-term intensification phase of treatment.

efficacy of 6-MP for rough a number of uld be unethical to conduct any efficacy studies with 6-MP in Europe. There is no doubt that 6-MP is considered integral to curing children with ALL. The the treatment of ALL is unquestioned and has been established over many years th national and international trials aimed at improving outcomes. Furthermore it wo

This application is to seek the indication of ALL for an oral 6MP liquid formulation where tablets are the only available formulation so far. This liquid alternative would allow treating patients (including adults) in whom tablets are not appropriate due to difficulties in swallowing. More important, it would solve the problem of dose adaptation in children since the currently available tablets make it necessary to crush or divide tablets with a risk of dosing error related to imprecision.

6-MP  is  titrated  according  to  haematological  response,  usually  measured  by  neutrophil  and  platelet counts. Therefore, the reliability  of  the  formulation  from  a  pharmacokinetic  point  of view  is  the  key factor  in  assessing  its  ability  to  induce  and  maintain  remission.  The  use  of  toxicity  as  a  factor  for determining over-dosing or under-dosing is common practice in cancer cytotoxic therapy as some level

<div style=\"page-break-after: always\"></div>

is  therefore more th a liquid formulation an exact measure  of  fluid of toxicity is required to achieve the desired anti-cancer effect. The toxicity target important than the actual dose  given.  Wi corresponding to the dose required is possible.

th  6-mercaptopurine  because 6-MP in the tablet In  this  application  no  further  clinical  efficacy  studies  were  provided  wi there is enough clinical experience from currently available data. In addition, oral form (Puri-Nethol) is already licensed in the EU for the treatment of ALL in Children.

ormulation to the paediatric patients. EU from use of the y children in terms The CHMP put special emphasis on the acceptability of the liquid f At the request of the CHMP the Applicant collected all data currently available in the proposed oral suspension to provide reassurance that the formulation is accepted b of palatability which may have implications on compliance (and thereby efficacy).

s a 'Special' to the RA Specials License) ented.  The Applicant claimed that the palatability and acceptability of Novapurine suspension r,  the  fact  that  no s  a  'Special'  is  not was not planned a Data from the availability of the product through continuous supply of the product a UK market (unlicensed medicine manufactured for individual patients under the MH were pres to  children  has  been  demonstrated since there have been no complaints. Howeve complaints  have  been  registered  from  patients  administered  with  Novapurine  a sufficient to provide reassurance on Novapurine palatability since this investigation priori.

on  the  'collective / palatability of the ion of pharmacist / ne suspension was ital;  in  two  hospitals  it  was  also  dispensed  for  adults.  This survey revealed the acceptability/palatability of the product in the paediatric population. The  Applicant  has  conducted  a  questionnaire  based  survey  to  obtain  feedback experience' of the hospital pharmacists, nurses and patients as to the acceptability formulation. The responses were from pharmacists (6), nurses (2) and a combinat nurse (2). The majority (8/10) of respondents stated that Nova's oral mercaptopuri dispensed  for  children  only  in  their  hosp cale for bitterness, tability throughout In addition, palatability of Novapurine was assessed in adults (n=6), on a 7-point s sweetness, sourness, saltiness. It reveals that the product maintains acceptable pala its proposed shelf life (0, 6 months, 12 months).

elay the children's m  either  patients r their carers (parents). The survey on children was limited to 10 participants (pharmacists, nurses) who r feeling  regarding  palatability.  This  information  should  have  been  retrieved  fro themselves (if age permits) o icant  proposed  to  conduct  a  study to  investigate  the a  prospective, open-label, single dose, non-randomised, questionnaire-based  survey  in  children  (aged  3-16  years)  with  acute  lymphoblastic  leukaemia.  The palatability tool for assessing the end points can be chosen following a thorough literature review, but hildren as well as l be discussed with Following  CHMP  recommendation  the  appl palatability of the product, in the context of is likely to be based on visual analogue/verbal scales. It is anticipated that young c adolescents will be recruited from leukaemia centres in the UK.  A full protocol wil the CHMP before a study is initiated.

## ficacy 2.5.2. Conclusions on the clinical ef

ptopurine  because in  the  tablet  form (Puri-Nethol) is already licensed in the EU for the treatment of ALL. This is in line with Scientific Advice given to the Applicant. In  this  application  no  further  clinical  efficacy  studies  were  provided  with  6-merca there  is  enough  clinical  experience  from  currently  available  data  since  oral  6-MP

At the request of the CHMP the Applicant collected all data currently available in the EU from use of the proposed oral suspension to provide reassurance that the formulation is accepted by children in terms of  palatability.  This  may  have  implications  on  compliance  (and  thereby  efficacy)  and  reassurance  is needed that compliance is not lower than it is for the tablet.

The bioequivalence study suggested that the two products have similar bioavailability (AUC) but that absorption was more rapid from the suspension, with a considerably higher Cmax. Given that the 6-MP dose  is  always  individually  titrated  based  on  haematological  response/toxicity,  and  since  toxicity  is coupled  to  the  pharmacological  action  of  6-MP,  it  is  agreed  that  additional  clinical  data  to  confirm efficacy  of  the  oral  suspension  are  not  considered  necessary,  despite  the  difference  in  rate  of

<div style=\"page-break-after: always\"></div>

uitable even for minimal dose adjustments. However, it should be confirmed that the formulation is acceptable to children. absorption compared with the tablet. In this respect, the liquid formulation is s

## 2.5.3. Recommendations for future clinical efficacy development

scientific progress, In the context of the obligation of the MAHs to take due account of technical and the CHMP recommends the following points for investigation:

- t  of  a  prospective, hildren (aged 3-16 years) with  acute  lymphoblastic  leukaemia.  The  palatability  tool  for  assessing  the  end  points  can  be chosen following a thorough literature review, but is likely to be based on visual analogue/verbal cipated that young children as well as adolescents will be recruited from leukaemia centres in the UK.  A full protocol will be discussed with the CHMP before a study is initiated.  The Applicant should investigate the palatability of the product, in the contex open-label, single dose, non-randomised, questionnaire-based survey in c scales. It is anti

## 2.6. Clinical safety

ed, because h  the  CHMP Scientific  advice  given  on  clinical  aspects  of  this  application.  Limited  additional  safety  data  were In this application, limited further clinical safety data with 6-mercaptopurine were provid there  is  adequate  clinical  experience  from  currently  available  data.  This  is  in  line  wit derived from the previously described bioequivalence study.

2.98  years.  Data  for  all  60 evaluation. 60  adult  healthy  volunteers  were  included  in  this  study.  The  Mean  age  was  2 volunteers entered for the study were included in the safety orally: In each of the two study periods, one of the following treatments was administered

Treatment A: 2.5 ml Mercaptopurine 20 mg/mLOral Suspension r, UK. Nova Laboratories Ltd., Leiceste

Treatment B: 1 x Puri-Nethol ® 50 mg tablet,

GlaxoSmithKline, UK.

blet) at each of the Volunteers were given a single 1 x 50 mg dose of 6-MP (as an oral suspension or ta two dosing visits with a washout period of at least 3 days between visits.

. One volunteer irty minutes after nge blood test -range blood tests In the bioequivalence study, three adverse events were recorded in three volunteers treated by Mercaptopurine 20 mg/mLOral Suspension had a headache three hours th dosing in Period 2. Two volunteers treated by Puri-Nethol 50 mg tablet had out-of-ra results at post study. The case of headache was treated with an icepack. The out-of were repeated, with satisfactory results.

There were no deaths, serious adverse events or significant adverse events.

biochemistry/haematology  results  slightly outside the laboratory ranges. Ten subjects had a slightly raised total bilirubin pre-study. These total bilirubin  increased  were  not  associated  with  elevated  AST  or  alkaline  phosphatase.    Post  study,  50 volunteers had one or more biochemistry/haematology results slightly outside the laboratory ranges. None  of  the  post  study  out-of-range  results  were  considered  by  the  Investigator  to  be  clinically significant,  with  the  exception  of  two  possible  related  events  of  moderate  intensity  of  reversible elevated  AST  (&gt;5  x  ULN  at  maximum  intensity)  in  one  subject  and  reversible  leucopenia  with neutropenia (Grade 1 CTCAE v4).  These two volunteers had received the tablet formulation as their second treatment. Repeat tests were carried out for these volunteers, with satisfactory results. At  pre-study  screening  52  volunteers  had  one  or  more

Elevated AST (&gt;5 x ULN at maximum intensity) and reversible leucopenia with neutropenia (Grade 1 CTCAE v4) are two adverse events included in 4.8 section of Puri-Nethol.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

base  of  the  recent t  combinatons  of al  suspension.  The on  to  the  trial  until  2008,  and ata on the incidence of stomatitis were analysed by the trial statistician at the Applicant's request and they are presented in the following table. The  issue  of  local  tolerance  has  been  investigated  in  the  pharmacovigilance  data UKALL2003  trial.  This  is  an  academic  trial  comparing  the  efficacy  of  differen chemotherapy for ALL and employs mercaptopurine in the form of both tablet or Applicant  was  the  principle  supplier  of  oral  mercaptopurine  suspensi afterwards remained one of two suppliers. D

Table 6: Incidence of stomatitis in the UKALL 2003

| Age Group (year's)   |   Totalnumberof recruitedpatients | Total Number (%) of Grade 3 /4Stomatitisreported   | Totalnumber(%)ofGrade 3/4stomatitisduring maintenancephase   |
|----------------------|-----------------------------------|----------------------------------------------------|--------------------------------------------------------------|
|                      |                              1270 | 97 (8.2)                                           | 18 (0.3)                                                     |
| 5-9                  |                               661 | 48 (7.7)                                           | 12 (0.3)                                                     |
| ≥10                  |                               677 | 74 (12.2)                                          | 5 (0.2)                                                      |

- a. Percentage of all toxicity reports

## 2.6.1. Discussion on clinical safety

The safety profile is of 6 MP is well known and derives from 50 years-clinical us related  toxicities  of  6-MP  (de  Vita  et  al,  2005)  are  myelosuppression  and  gastr Gastrointestinal to e.  The major doseointestinal  toxicity. xicities include nausea and vomiting, anorexia, diarrhoea, and stomatitis.

a  is  observed  less ful monitoring of nd  platelet  counts e fall in the counts, reversible if  6ction to 5% to 25% also discussion on Leukopenia  and  thrombocytopenia  are  maximal  7  days  after  treatment.  Anaemi frequently. Full haematologic recovery usually occurs after 14 days. Care haematological  parameters  should  be  conducted  during  therapy.  The  leucocyte  a continue to fall after treatment is stopped, so at the first sign of an abnormally larg treatment should be interrupted immediately. Bone marrow suppression is mercaptopurine is withdrawn early enough. In TPMT-deficient patients, dosage redu of the standard dosage (75 mg/m 2 /d) is necessary to prevent excessive toxicity (see clinical pharmacology).

ow fever vaccine is potential  to  cause m vaccines are not Finally, due to myelosuppression, the concomitant use of mercaptopurine with yell contraindicated.  Moreover,  immunisation  using  a  live  organism  vaccine  has  the infection in immunocompromised hosts. Therefore, immunisations with live organis recommended.

manifested mainly be seen. Hepatotoxicity sis can occur after d be avoided, liver  toxicity  is  not to  a  hepatotoxic r accumulation of 6-MP metabolites in the liver. Liver function tests should be monitored weekly during treatment. More frequent monitoring may be advisable in those with pre-existing liver disease  or  receiving  other  potentially  hepatotoxic  therapy.  The  patient  should  be  instructed  to discontinue Mercaptopurine Nova Laboratories immediately if jaundice becomes apparent 6-MP is hepatotoxic and hepatotoxicity occurs in up to 30% of adult patients and is as cholestatic jaundice, although elevations of hepatic transaminases may also is usually mild and reversible after discontinuation of 6-MP, but frank hepatic necro high doses of the drug. Combinations of 6-MP with other known hepatotoxic agents shoul and  liver  function  test  results  should  be  closely  monitored.  The  mechanism  of known  but  may  relate  to  the  cytochrome  P-450-dependent  metabolism  of  6-MP metabolite o

Similarly,  during  remission  induction  when  rapid  cell  lysis  is  occurring,  uric  acid  levels  in  blood  and urine should be monitored as hyperuricaemia and/or hyperuricosuria may develop, with the risk of uric acid nephropathy. Hydration and urine alkalinisation may minimize potential renal complications.

Pancreatitis has been reported to occur at a frequency of ≥ 1/100 to &lt; 1/10 ('common') in patients treated for inflammatory bowel disease.

One bioequivalence study to bridge the existing knowledge with the new formulation was submitted. Only three adverse events were collected from the bioequivalence study: Headache, elevated AST and leucopenia  with  neutropenia  and  these  are  in  line  with  the  known  adverse  event  profile  of mercaptopurine.

<div style=\"page-break-after: always\"></div>

haryngeal mucosa, t  was  questioned f oral mucositis. Since treatment with mercaptopurine per se is associated with toxicity on the orop potential  additional  adverse  effects  caused  by  topical  exposure  were  discussed  as  i whether the pharmaceutical formulation may promote or worsen the potential risk o f the proposed oral l  suspension  with lerance The Applicant was asked to collect all data currently available in the EU from use o suspension  to  provide  reassurance  on  the  local  tolerance  of  mercaptopurine  ora special  attention  to  chemotherapy-induced  oral  mucositis.  The  issue  of  local  to has  been l. The analysis was s. investigated through the pharmacovigilance database of the recent UKALL2003 tria conducted by the UKALL2003 trial statistician and at the request of Nova Laboratorie

ons  (tablet  versus xicity data collected 2000  children  suggests  that  potential  differences in  local  exposure  to ect  on  the  rates  of s also presented to evaluation of local ce in their final opinion. Although  a  specific  evaluation  of  the  effect  of  oral  mercaptopurine  formulati suspension) on rates of local toxicity was not an a priori objective of UKALL2003, to thus  far in  excess  of mercaptopurine as a consequence of formulation does not appear to have an eff stomatitis, which overall are very low during the maintenance phase. This data wa the PDCO during the PIP application, who consequently waived the need for further toleran

The rates of stomatitis are very low (0.2- 0.3%) in all age categories during the maintenance phase of omatitis are higher tween 5-10 years. olescent leukaemic therapy, where mercaptopurine is predominantly administered. The total rates of st in children over 10 years old, than in children under 5 years old or those aged be This is not surprising since it is known that incidence of all toxicity is higher in ad subjects.

l  tolerance  are  also  supported  by  the  known  pharmacology  of mercaptopurine.  The ic  absorption  and llowing first pass metabolism in the liver. Oro-pharyngeal toxicity is therefore influenced by systemic exposure and not ill  be  minimal and overwhelming  levels  of  circulating  TGNs  following  liver  activation  (first The data on loca anti-proliferative  and  cytotoxic  pharmacology  of  mercaptopurine requires  system activation to thioguanine nucleotides (TGNs)  which are principally formed  fo local exposure and any theoretical local (epithelial) activation of mercaptopurine w insignificant  relative  to  the pass) of an oral dose.

lalanine and it may ful for people with phenylketonuria. Mercaptopurine Nonva Laboratories contains aspartame (E951), a source of pheny be harm ch  may  cause It  also  contains  methyl  parahydroxybenzoate  and  propyl  parahydroxybenzoates  whi allergic reaction (possibly delayed).

of  fructose  intolerance, on  or  sucrase-isomaltase  insufficiency  should  not  take  this  medicine. dental hygiene is As  this  medicine  contains  sucrose,  patients  with  rare  hereditary  problems glucose-galactose  malabsorpti Long term use increases the risk of dental caries and it is essential that adequate maintained.

be early symptoms of n e Nova Laboratories. Liver dysfunction and gastroenteritis may s being given Gastrointestinal effects, including nausea, vomiting, diarrhoea and anorexia may overdose having occurred. The principal toxic effect is on the bone marrow, resulting i myelosuppression. Haematological toxicity is likely to be more profound with chronic overdose than with a single ingestion of Mercaptopurin also occur. The risk of overdose is also increased when xanthine oxidase inhibitors i concomitantly with 6-mercaptopurine.

general supportive ive measures (such as the use of activated charcoal or gastric lavage) may  not  be  effective in the event of 6-mercaptopurine overdose unless the procedure can be undertaken within 60 minutes of ingestion. As there is no known antidote the blood picture should be closely monitored and measures, together with appropriate blood transfusion, instituted if necessary. Act

Parents and care givers should avoid Mercaptopurine Nova Laboratories contact with skin or mucous membrane.  If  the  suspension  comes  into  contact  with  skin  or  mucosa,  it  should  be  washed immediately and thoroughly with soap and water.

6MP oral suspension has been developed for children who cannot swallow or for whom precise dosing cannot be achieved by splitting tablets, meaning 3-6 years-old, less than 50 kgs children.

Considering that the weight range for children will be [10-50] kgs, with a 100 mg/5ml concentration and a 2.5 mg/kg posology, the volume administered ranges from 1.25 to 6.5 ml. The applicant has demonstrated precise measurement of the administered volume by the syringes provided. It is agreed

<div style=\"page-break-after: always\"></div>

,  0.2  ml  increments  will  provide  sufficient  precision  in  dosage,  given  the that  for  doses  above  1  ml overall pharmacokinetic variability.

equate precautions rors have occurred more, the 1 ml  syringe  will  be n  colour,  and  in  the  5  ml  syringe  it  will  be  'white'  in  colour.  This  will  ensure  that  the  two ct launch following ion are part of the As 2 syringes are included in the pack, a risk of dosing error cannot be excluded. Ad and instructions have been included in the Product Information. So far no such er from the availability of the product as 'special' in a number of EU member states. Further ml  and  5  ml  syringes  will  be  provided  in  different  colours.  The  plunger  in  the  1 'purple'  i syringes are clearly distinguishable. The proposed syringes will be available at produ MA approval. Surveillance of medication errors as a consequence of syringe confus PV strategy.

At the recommendation of the CHMP, the applicant agreed to add overpacks for each syringe on which 1 mL syringe and 'dose more than 1 mL' \"  will be printed nge  to  clarify  to  the  patient  or  the  caregiver  which  devices  is  appropriate  for  the 'dose less than 1 mL' will be printed on the on  the  5  mL  syri desired volume to be drawn into the syringe.

## 2.6.2. Conclusions on the clinical safety

years-clinical  use.  The  most  frequent  adverse  reactions include stomatitis, nausea, vomiting, anorexia, gastro-intestinal ulceration and bleeding, The  safety  profile  of  6  MP  derives  from  50 hepatotoxicity, bone marrow toxicity and immune suppression.

cal exposure would antly  contribute  to  oro-pharyngeal  toxicity.  It  is  suggested  that  any  signals  relating  to  local toxicity issues are handled within the PSUR framework. Based on the pharmacology of 6-mercaptopurine, it is considered unlikely that lo signific ns  and  warnings  in  the  product information.  Routine  Pharmacovigilance  strategy  will  be  sensitive  to  such  dosing  errors,  such  as  or n  is  part  of  the  PV The  potential  risk  of  dosing  is  addressed  with  appropriate  instructio example, surveillance  of  medication  errors  as  a  consequence  of  syringe  confusio strategy.

## 2.6.3.  Recommendations for future clinical safety development

dd overpacks for each syringe on which the text \"dose less than 1 ml\" would be printed on the 1 ml syringe and \"dose more than 1 ml\" would be evice is adapted to uld be used for withdrawing the liquid. Furthermore, the CHMP recommends to the Applicant to a printed on the 5 ml syringe. This will explain the patient or the caregiver which d the volume and sho

## 2.7 Pharmacovigilance

## Detailed description of the Pharmacovigilance system

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## Risk Management plan

The CHMP did not require the applicant to submit a risk management plan because it is accepted that risk management plans are generally not required for hybrid products where the active substance has been  on  the  market  for  a  long  time,  unless  a  safety  concern  requiring  additional  risk  minimisation activities has been identified with the reference product. This argument is considered relevant for the substance itself.

<div style=\"page-break-after: always\"></div>

pital  setting,  risks ated  with  handling  and  dosing  have  been  addressed  by  adequate  instructions  in  the  Package As  the  product  is  intended  for  self-  (or  parent-)  administration  outside  of  a  hos associ Leaflet.

Surveillance of medication errors as a consequence of confusion with the use of syringes is part of the routine Pharmacovigilance strategy.

harmacovigilance uate to monitor the safety of the product. The CHMP, having considered the data submitted, was of the opinion that routine p was adeq inimisation  activities  were  required  beyond  those  included  in  the  product No  additional  risk  m information.

## 2.8 User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the p aflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. ap licant show that the package le

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

6-MP remains an integral part of ALL treatment protocols in children. So far, the only licensed product d, but in practice this has to be done in order to find an appropriate dose for the individual patient. on the EU market is a 50 mg tablet, which should not be divide ematologic toxicity. an oral suspension provides  better  accuracy  and  ease  of  administration  in  small  children.  From  an  efficacy  as  well  as safety perspective this is favourable. During therapy of ALL, the dose of 6-MP is individualised, essentially based on ha Compared with tablets, which is the only currently available licensed formulation,

## e knowledge about the beneficial effects. Uncertainty in th

for the paediatric commended  to  the aboratories. Considering that palatability is sometimes a concern for oral formulations intended population  as  it  may  be  associated  with  compliance  to  the  drug,  the  CHMP  re applicant to perform a survey investigating the palatability of Mercaptopurine Nova L

## Risks

## Unfavourable effects

The  dose-limiting  toxicity  is  the  haematological  effect.  As  the  mercaptopurine  dose  is  individually titrated based on haematological response, no additional systemic toxicity  is  expected  from  the  oral suspension compared with the previously approved tablet. If a switch from tablets to oral suspension, or vice versa, is undertaken, the physician, patients and parents should be made aware that the dose may need to be adjusted.

<div style=\"page-break-after: always\"></div>

## Uncertainty in the knowledge about the unfavourable effects

raben  as  preservative  was questioned, but the exposure of the patient is low, well below the lowest observed adverse event level. e future. From  a  Quality  and  Non-clinical  perspective,  the  choice  of  propylpa Nevertheless, it is recommended to the Applicant to eliminate this preservative in th

An increased risk for local toxicity with the Novapurine formulation seems unlikely but has not been issues are handled prospectively addressed. It is suggested that any signals relating to local toxicity within the PSUR framework.

fusion with the inclusion of 2 different syringes in the pack is expected to be well ur coding of the pack. Signals of such potential errors will be detected through A potential risk of con managed by the colo routine pharmacovigilance.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

ease of administration especially when n  and  this  is  important  from  an  efficacy  as  well  as  safety  perspective.  The haematological toxicity is part of the action of mercaptopurine, well managed by titration of the drug be better managed purine Nova Laboratories. The availability of a suspension provides better accuracy and used  in  small  childre for individual use. The well known toxicity profile of mercaptopurine is expected to with more accurate dosing achieved with Mercapto

## Benefit-risk balance

20  mg/ml  for  the The  benefit-risk  balance  of  Mercaptopurine  Nova  Laboratories  oral  suspension treatment of Acute Lymphoblastic Leukaemia is positive.

## sk balance Discussion on the benefit-ri

Historically, the risk-benefit profile of 6-MP for the treatment of ALL have been well established based the EU and other developed countries. Mercaptopurine Nova Laboratories oral suspension ensures better precision and ease of administration tion for children who hat  also  allows  more on numerous multi-centre, multi-national trials in than the existing tablet form and importantly, it will provide an alternative formula are  unable  to  swallow  tablets,  and  for  clinicians,  an  alternative  preparation  t flexible dosing.

## mendations 4. Recom

## Similarity with authorised orphan medicinal products

aboratories is not similar to Atriance, Evoltra, Glivec or Sprycel within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix The CHMP by consensus decision is of the opinion that Mercaptopurine Nova L

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Mercaptopurine Nova Laboratories in the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children is favourable and therefore recommends  the granting of the marketing authorisation subject to the following conditions:

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

to restricted medical prescription (See Annex I: Summary of Product Medicinal product subject Characteristics, section 4.2).

## ts of the Marketing Authorisation Conditions and requiremen

## Risk Management System and PSUR cycle

e 1.8.1 of the marketing authorisation, is in place and functioning before and whilst the product is on the market. The MAH must ensure that the system of pharmacovigilance, presented in Modul

The PSUR cycle for the product will follow the standard requirements until otherwise agreed by the CHMP.

## gard to the safe and effective use of the medicinal product Conditions or restrictions with re

ble Not applica ns or restrictions with regard to the safe and effective use of the medicinal product Conditio to be implemented by the Member States.

Not applicable.

## References

Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia. Leukaemia Res 1994; 18: 805-810.

Borel  Y  &amp;  Schwartz  R.  Inhibition  of  Immediate  and  Delayed  Hypersensitivity  in  the  Rabbit  by  6Mercaptopurine. Journal of Immunology 1964; 92:754-761.

tudies on different rapy, 2007; 8 (1.) Breitkeutz J, Buckham J, Fischer R, PÖstges R, et al (2007). Comparative in vitro s 6-mercaptopurine formulations for use in children. Paediatric and Perinatal Drug The

DA,  Craver  LF, aptopurine,  in  the 99 Burchenal  JH,  Murphy  ML.,  Ellison  RR,  Sykes  PM,  Tan  TC,  Leone  LA,  Karnof-  Sky Dargeon  HW,  Rhoads  CP.  Clinical  Evaluation  of  a  New  Antimetabolite,  6-Merc Treatment of Leukemia and Allied Diseases Blood 1953; 8(11): 965-9

CF7 human breast Byford JR, Shaw LE, Drew MGB, et al (2002). Oestrogenic activity of parabens in M cancer cells. Journal of Steroid Biochemistry &amp; Molecular Biology 80 (2002) 49-60

lative Skin Irritation, Sensitization and Effect of d -Limonene on Permeation of 6- Mercaptopurine through Transdermal Drug Chandrashekar NS  &amp; Hiremath SRR. In Vivo Immunomodulatory,  Cumu Delivery Biol. Pharm. Bull. 2008; 31(4): 656-661

Clarke  DA,  Philips  FS,  Sternberg  SS,  Stock  CC,  Elion  GB,  Hitchings  GH  (1953)  6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. Cancer Res. 13(8):593-604

Coulthard S, Hogarth L. The thiopurines: An update. Investigational New Drugs 2005; 23: 523-532 da Silva CP, de Oliveira CR, de Lim M et al, (1996). Apoptosis as a Mechanism of Cell Death Induced by Different Chemotherapeutic Drugs in Human Leukemic T-Lymphocytes. Biochemical Pharmacology, Vol. 51, pp. 1331-1340, 1996

deVita VT, hellman S, Rosenberg SA CANCER principles and Practice of Oncology (2005) 7 th  edition

EFSA (2003). Survey of intense sweeteners in dilutable drinks prepared for young children

<div style=\"page-break-after: always\"></div>

ng  Aids  and Materials in Contact with Food on a Request from the Commission related to para hydroxybenzoates (E EFSA  (2004).  Opinion  of  the  Scientific  Panel  on  Food  Additives,  Flavourings,  Processi 214-219)

ng  Aids  and mission  related  to  a  new  long  term 06; 356: 1-44. Opinion of the Scientific Panel on Food: Update on the safety of aspartame (SCF,2002) EFSA  (2006).  Opinion  of  the  Scientific  Panel  on  Food  Additives,  Flavourings,  Processi Materials  in  contact  with  food  on  a  request  from  the  com carcinogenicity study on aspartame. The EFSA Jouinal20

Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47

ment on European Aspartame Study (2007) FDA State e Andrea ML. Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. Oral Diseases (2008) Figliolia SLT, Oliveira DT, Pereira MC, Lauris JRP, Maurício AR, Oliveira DT, Mello d 14, 761-766

n Cancer Res 1998; Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Cli 4: 1-6

Golden R, Gandy J, Vollmer G (2005). A Review of the Endocrine Activity of Parabens and Implications for Potential Risks to Human Health.

and Methylparaben 33, 2008 Hoberman AM, Schreur DK, Leazer T, et al (2008). Lack of Effect of Butylparaben on the Reproductive System in Male Rats. Birth Defects Research (Part B) 83:123-1

and Isobutyl ρ -ates administered orally to mice. Ed Chem Toxic. Vol 23, No. 6, PP. 575-578, 1985 Inai K, Aoki Y, Akamizu H, et al (1985). Tumorigenicity study of Butyl Hydroxybenzo urine is compatible ne  into  DNA  as  6Inamochi H, Higashigawa M, Shimono Y et al.,. Delayed cytotoxicity of 6- mercaptop with  mitotic  death  caused  by  DNA  damage  due  to  incorporation  of  6-thioguani thioguanine nucleotide. J Exp Clin Cancer Res. 1999; 18(3): 417-424

Innocenti F, Danesi R, Bocci G, Fogli S, Di Paolo A, Del Tacca M. Metabolism of 6-mercaptopurine in the mother  Pharmacol erythrocytes,  liver,  and  kidney  of  rats  during  multipledose  regimens.  Cancer  Che 1999;43: 133-140

of  Pharmaceutical P, Weller P). London: Pharmaceutical Press. Wering ER et astic leukaemia. Blood 1995; 86: 3861-3868 Johnson  and  Steer  (2005).  Handbook  of  Pharmaceutical  Excipients.  In  Handbook Excipients 2005 5th Edition (editors: Raymond R, Sheskey Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van al.,. In vitro cellular drug resistance in children with relapsed/refractory acute lymphobl n of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylatio Mol Pharmacol 1995; 47: 1141-1147

Law  LW,  Taormina  V  and  Boyle  PJ  (1954).  Response  of  acute  lymphocytic  leukemias  to  the  purine antagonist 6-mercaptopurine. Ann. N Y Acad Sci. 1954; 6;60(2); 244-50

Law  LW.  Studies  on  transformations  in  leukemic  cells  of  the  mouse.  J  Natl  Cancer  Inst.  1954; 15(3):817-34

Lönnerholm  G,  Kreuger  A,  Lindström  B,  Myrdal  U    Oral  mercaptopurine  in  childhood  leukemia: influence of food intake on bioavailability. Pediatr Hematol Oncol. 1989;6(2):105-12.

Ling YH, Chang JY, Beattie KL, et al (1992). Consequences of 6-Thioguanine Incorporation into DNA on Polymerase, Ligase, and Endonuclease Reactions. Molecular Pharmacology, 42:802-807

<div style=\"page-break-after: always\"></div>

enicity study of 6-mercaptopurine in F344 Maekawa A, Nagaoka T, Onodera H et al. Two year carcinog rats. Journal of Cancer Research and Clinical Oncology. 1990, Vol 116 No. 3

Medical Research Council Working Party on Leukaemia in Children UK National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia (ALL). UKALL 2003

6(3):279-94 Mosesso P, Palitti F. The genetic toxicology of 6-mercaptopurine. Mutat Res.1993; 29

urine (6MP) in the ug  Metab  Dispos. 1983 Jan-Feb;11(1):5-9 Narang PK, Chatterji DC, O'Neill D, Poplack DG. Pharmacokinetics of 6- mercaptop monkey.  I.  Disposition  from  plasma  and  cerebrospinal  fluid  following  iv  bolus.  Dr ce on the Non-clinical Local Tolerance Testing of Medicinal Products, Note for Guidan CPMP/SWP/2145/00

Oishi  S.  Effects  of  butylparaben  on  the  male  reproductive  system  in  rats.  Toxicology  and  Industrial Health 2001; 17: 31-39

Arch Toxicol (2002) Oishi S (2002a). Effects of butyl paraben on the male reproductive system in mice. 76: 423-429

ood  and  Chemical Oishi  S  (2002b).  Effects  of  propyl  paraben  on  the  male  reproductive  system.  F Toxicology 40 (2002) 1807-1813

xybenzoic acid in Oishi S (2004). Lack of spermatotoxic effects of methyl and ethyl esters of phydro rats. Food and Chemical Toxicology 42 (2004) 1845-1849

purine and related Philips FS, Sternberg SS, Hamilton S, Clarke DA. The toxic effects of 6- mercapto compounds. Ann N Y Acad Sci. 1954 6;60(2):283-96

n der Does-van den Berg A, van Wering e activities with Leukaemia Res 16: Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, va ER, Veerman AJP. (1992) Relation of 5'-nucleotidase and phosphatas immunophenotype, drug resistance and clinical prognosis in childhood leukaemia. 873-880

ent  of  inflammatory ty. Ann Intern Med 1989; 111: 641-649 Present  DH,  Meltzer  SJ,  Krumholz  MP  et  al.  6-Mercaptopurine  in  the  managem bowel disease: short and long term toxici

Product Monograph Purinethol (2003), Novopharm Limited, Toronto, Canada

Riccardi R, Balis FM, Ferrara P, Lasorella A, Poplack DG, Mastrangelo R. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1986;3(4):319-24.

Rivard GE, Lin KT, Leclerc JM, David M Milk could decrease the bioavailability of 6-mercaptopurine. Am J Pediatr Hematol Oncol. 1989 Winter;11(4):402-6.

Routledge ER, Parker J, Odum J, et al (1998). Some Alkyl Hydroxy Benzoate Preservatives (Parabens) Are Estrogenic. Toxicology and Applied Pharmacology. 153, 12-19, 1998

Sasaki H, Tsuru K, Nakamura J, Konishi R, Shibasaki J. Effect of allopurinol on the intestinal absorption of 6-mercaptopurine in rats. J Pharmacobiodyn. 1987;10:697-702

Scientific Committee on Food (2002). Update on the safety of Aspartame

Shi RZ, Lyons SD, Christopherson RI. Metabolic effects of thiopurine derivatives against human CCRFCEM leukaemia cells. Int J Biochem Cell Biol 1998; 30: 885±895

<div style=\"page-break-after: always\"></div>

Sofianou-Katsoulis A, Khakoo G, Kaczmarski R Reduction in bioavailability of 6-mercaptopurine on simultaneous administration with cow's milk. Pediatr Hematol Oncol (2006) Sept 23 (6) 485-7

Soni  MG,  Carabin  IG,  Burdock  GA  (2005).  Safety  assessment  of  esters  of  phydroxybenzoic  acid (parabens). Food and Chemical Toxicology 43 (2005) 985-1015

Stet EH, De Abreu RA, Bokkerink JP, Lambooy LH, Vogels- Mentink TM, Keizer-Gerritsen JJ, Trijbels FJ. adenine.  Biochem Reversal  of  methylmercaptopurine  cytotoxicity  by  purine  ribonucleotides  and Pharmacol 1995; 49: 49-56

n the growth of a f mouse and rat tumors. Proc. Am. A. Cancer Res. 1953; 1: 55 Sugiura K. The effect of 6-thiopurimie amid of 1,9-di(methanesulfomioxy)nonane o variety o syl pyrophosphate otides. Biochem Pharmacol 1968; Tay BS, Lilley RMC, Murray AW, Atkinson MR. Inhibition of phosphoribo amidotansferase from Erlich ascites-tumour cells by thiopurine nucle 18: 936-938

Thomsen  JB,  Schroder  H,  Kristinsson  J  et  al.,.  Possible  Carcinogenic  Effect  of  6-Mercaptopurine  on -6 Bone Marrow Stem Cells. Relation to Thiopurine Metabolism.Cancer 1999; 86: 1080

ic reaction of  6Tidd DM,  Paterson ARP. A biochemical mechanism  for  the delayed cytotox mercaptopurine. Cancer Res 1974; 34: 738-746

macokinetics  of  6Tterlikkis  L,  Day  JL,  Brown  DA,  Schroeder  EC.  Effect  of  Allopurinol  on  the  Phar Mercaptopurine in Rabbits. Cancer Res 1983; 43:1675-1679

Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based continuing therapy. Cancer Res 1995; 55: 1670-1674

Zimm S, Johnson GE, Chabner BA, Poplack DG. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res 1985; 45:4156-4161